0001493152-20-021529.txt : 20201116 0001493152-20-021529.hdr.sgml : 20201116 20201116115557 ACCESSION NUMBER: 0001493152-20-021529 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201116 DATE AS OF CHANGE: 20201116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sintx Technologies, Inc. CENTRAL INDEX KEY: 0001269026 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33624 FILM NUMBER: 201314769 BUSINESS ADDRESS: STREET 1: 1885 WEST 2100 STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84119 BUSINESS PHONE: 801-839-3516 MAIL ADDRESS: STREET 1: 1885 WEST 2100 STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84119 FORMER COMPANY: FORMER CONFORMED NAME: AMEDICA Corp DATE OF NAME CHANGE: 20121231 FORMER COMPANY: FORMER CONFORMED NAME: AMEDICA CORP DATE OF NAME CHANGE: 20031104 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-33624

SINTX Technologies, Inc.

(Exact name of registrant as specified in its charter)

DELAWARE		84-1375299
(State or other jurisdiction		(IRS Employer
of incorporation or organization)		Identification No.)

1885 West 2100 South, Salt Lake City, UT		84119
(Address of principal executive offices)		(Zip Code)

(801) 839-3500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock		SINT		The NASDAQ Capital Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days: Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files); Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	[ ]	Accelerated filer	[ ]

Non-accelerated filer	[ ]	Smaller reporting company	[X]

		Emerging growth company	[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

25,551,059 shares of common stock, $0.01 par value, were outstanding at November 10, 2020

SINTX Technologies, Inc.

Table of Contents

Part I. Financial Information
Item 1. Financial Statements
Condensed Consolidated Balance Sheets (unaudited)	3
Condensed Consolidated Statements of Operations (unaudited)	4
Condensed Consolidated Statements of Stockholders’ Equity (unaudited)	5
Condensed Consolidated Statements of Cash Flows (unaudited)	6
Notes to Condensed Consolidated Financial Statements (unaudited)	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3. Quantitative and Qualitative Disclosures About Market Risk	23
Item 4. Controls and Procedures	23
Part II. Other Information
Item 1. Legal Proceedings	24
Item 1A. Risk Factors	24
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3. Defaults Upon Senior Securities	24
Item 4. Mine Safety Disclosures	24
Item 5. Other Information	24
Item 6. Exhibits	25
Signatures	26

SINTX Technologies, Inc.

Condensed Consolidated Balance Sheets - Unaudited

(in thousands, except share and per share data)

	September 30, 2020			December 31, 2019

Assets
Current assets:
Cash and cash equivalents	$	27,050		$	1,787
Account and other receivables		49			136
Prepaid expenses and other current assets		225			310
Inventories, net		74			106
Notes receivable, current portion		2,189			1,724
Total current assets		29,587			4,063

Inventories, net		461			533
Property and equipment, net		287			190
Intangible assets, net		37			41
Long-term note receivable, net of current portion		194			1,944
Operating lease right-of-use-asset		2,031			2,341
Other long-term assets		36			35
Total assets	$	32,633		$	9,147

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	157		$	191
Accrued liabilities		946			1,266
Derivative liabilities		1,600			220
Current portion of operating lease liability		393			360
Current portion of debt		238			6
Other current liabilities		25			23
Total current liabilities		3,359			2,066

Operating lease liability, net of current portion		1,580			1,867
Long term debt		158			12
Total liabilities		5,097			3,945

Commitments and contingencies

Stockholders’ Equity:
Convertible preferred stock Series B, $0.01 par value, 130,000,000 total shares authorized inclusive of all series of preferred; 26 shares and 249 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively.		-			-
Convertible preferred stock Series C, $0.01 par value, 130,000,000 total shares authorized inclusive of all series of preferred; 51 shares and 0 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively.		-			-
Common stock, $0.01 par value, 250,000,000 shares authorized; 24,551,059 shares, and 2,434,009 shares issued and outstanding at September 30, 2020 and December 31, 2019.		246			24
Additional paid-in capital		266,665			239,256
Accumulated deficit		(239,375	)		(234,078	)
Total stockholders’ equity		27,536			5,202
Total liabilities and stockholders’ equity	$	32,633		$	9,147

The condensed consolidated balance sheet as of December 31, 2019, has been prepared using information from the audited consolidated balance sheet as of that date.

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX Technologies, Inc.

Condensed Consolidated Statements of Operations - Unaudited

(in thousands, except share and per share data)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Product revenue	$	66		$	173		$	478		$	437
Costs of revenue		53			151			382			364
Gross profit		13			22			96			73
Operating expenses:
Research and development		1,432			869			3,494			2,557
General and administrative		827			714			2,418			2,166
Sales and marketing		182			139			450			303
Total operating expenses		2,441			1,722			6,362			5,026
Loss from operations		(2,428	)		(1,700	)		(6,266	)		(4,953	)
Other income (expenses):
Interest expense		(1	)		(1	)		(2	)		(3	)
Interest income		78			111			267			349
Change in fair value of derivative liabilities		(287	)		144			1,750			754
Offering costs		-			-			(1,246	)		-
Other income, net		201			-			201			48
Total other income (expense), net		(9	)		254			970			1,148
Net loss before income taxes		(2,437	)		(1,446	)		(5,296	)		(3,805	)
Provision for income taxes		-			-			-			-
Net loss		(2,437	)		(1,446	)		(5,296	)		(3,805	)
Deemed dividend related to the beneficial conversion feature and accretion of a discount on series B preferred stock		(74	)		(345	)		(9,565	)		(2,703	)
Net loss attributable to common stockholders	$	(2,511	)	$	(1,791	)	$	(14,861	)	$	(6,508	)

Net loss per share – basic and diluted
Basic – net loss	$	(0.11	)	$	(0.68	)	$	(0.39	)	$	(3.00	)
Basic - deemed dividend and accretion of a discount on conversion of preferred stock		-			(0.16	)		(0.70	)		(2.13	)
Basic – attributable to common stockholders	$	(0.11	)	$	(0.84	)	$	(1.09	)	$	(5.13	)

Diluted –net loss	$	(0.11	)	$	(0.75	)	$	(0.49	)	$	(3.59	)
Diluted - deemed dividend and accretion of a discount on conversion of preferred stock		-			(0.16	)		(0.63	)		(2.13	)
Diluted – attributable to common stockholders	$	(0.11	)	$	(0.91	)	$	(1.12	)	$	(5.72	)
Weighted average common shares outstanding:
Basic		22,774,263			2,127,293			13,671,866			1,269,106
Diluted		22,774,263			2,127,293			15,094,276			1,269,106

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX Technologies, Inc.

Condensed Consolidated Statements of Stockholders’ Equity - Unaudited

(in thousands, except share and per share data)

	Preferred B Stock					Preferred C Stock				Common Stock				Paid-In			Accumulated			Total
	Shares			Amount		Shares		Amount		Shares		Amount		Capital			Deficit			Equity
Balance as of December 31, 2018		4,074		$	-		-	$	-		726,455	$	7	$	237,673		$	(229,281	)	$	8,399
Net loss		-			-		-		-		-		-		-			(1,629	)		(1,629	)
Balance as of March 31, 2019		4,074			-		-		-		726,455		7		237,673			(230,910	)		6,770
Common stock issued from exercise of warrants for cash		-			-		-		-		500		-		2			-			2
Common stock issued due to conversion of preferred stock		(3,337	)		-		-		-		983,528		10		(10	)		-			-
Stock based compensation		-			-		-		-		-		-		1			-			1
Common stock issued for cash, net of fees		-			-		-		-		144,415		1		395			-			396
Removal of derivative liability upon exercise of warrant		-			-		-		-		-		-		1			-			1
Net loss		-			-		-		-		-		-		-			(730	)		(730	)
Balance as of June 30, 2019		737			-		-		-		1,854,898		18		238,062			(231,640	)		6,440
Common stock issued from exercise of warrants for cash		-			-		-		-		35,374		-		101			-			101
Common stock issued for cash, net of fees		-			-		-		-		313,463		4		886			-			890
Common stock issued due to conversion of preferred stock		(488	)		-		-		-		160,256		2		(2	)		-			-
Stock based compensation		-			-		-		-		-		-		-			-			-
Removal of derivative liability upon exercise of warrant		-			-		-		-		-		-		43			-			43
Net loss		-			-		-		-		-		-		-			(1,446	)		(1,446	)
Balance as of September 30, 2019		249		$	-		-	$	-		2,363,991	$	24	$	239,090		$	(233,086	)	$	6,028

	Preferred B Stock					Preferred C Stock					Common Stock				Paid-In			Accumulated			Total
	Shares			Amount		Shares			Amount		Shares		Amount		Capital			Deficit			Equity
Balance as of December 31, 2019		249		$	-		-		$	-		2,434,009	$	24	$	239,256		$	(234,078	)	$	5,202
Extinguishment of derivative liability upon exercise of warrant		-			-		-			-		-		-		1,557			-			1,557
Issuance of common stock from the exercise of warrants for cash		-			-		-			-		100		-		-			-			-
Issuance of common stock from the cashless exercise of warrants		-			-		-			-		3,128,895		32		(32	)		-			-
Preferred stock issued for cash, net of fees		-			-		9,440			-		-		-		3,112			-			3,112
Common stock issued on conversion of preferred stock		-			-		(9,208	)		-		6,215,742		62		(62	)		-			-
Issuance of agent warrants		-			-		-			-		-		-		168			-			168
Beneficial conversion feature on issuance of convertible preferred stock		-			-		-			-		-		-		3,111			-			3,111
Deemed dividend related to the issuance of preferred stock		-			-		-			-		-		-		(3,111	)		-			(3,111	)
Accretion of convertible preferred stock discount		-			-		-			-		-		-		6,173			-			6,173
Deemed dividend related to the conversion of preferred stock		-			-		-			-		-		-		(6,173	)		-			(6,173	)
Net income		-			-		-			-		-		-		-			1,169			1,169
Balance as of March 31, 2020		249			-		232			-		11,778,746		118		243,999			(232,909	)		11,208
Extinguishment of derivative liability upon exercise of warrant		-			-		-			-		-		-		1,451			-			1,451
Common stock issued for cash, net of fees		-			-		-			-		6,454,381		65		9,583			-			9,648
Issuance of common stock from the cashless exercise of warrants		-			-		-			-		373,750		3		(3	)		-			-
Issuance of common stock from the exercise of warrants for cash		-			-		-			-		611,868		6		911			-			917
Common stock issued on conversion of preferred stock		(123	)		-		(179	)		-		212,168		2		(2	)		-			-
Accretion of convertible preferred stock discount		-			-		-			-		-		-		207			-			207
Deemed dividend related to the conversion of preferred stock		-			-		-			-		-		-		(207	)		-			(207	)
Net loss		-			-		-			-		-		-		-			(4,028	)		(4,028	)
Balance as of June 30, 2020		126			-		53			-		19,430,913		194		255,939			(236,937	)		19,196
Extinguishment of derivative liability upon exercise of warrant		-			-		-			-		-		-		190			-			190
Stock based compensation		-			-		-			-		-		-		29			-			29
Common stock issued for cash, net of fees		-			-		-			-		4,915,000		50		10,318			-			10,368
Issuance of common stock from the cashless exercise of warrants		-			-		-			-		1,890		-		-			-			-
Issuance of common stock from the exercise of warrants for cash		-			-		-			-		127,650		1		190			-			191
Common stock issued on conversion of preferred stock		(100	)		-		(2	)		-		75,606		1		(1	)		-			-
Accretion of convertible preferred stock discount		-			-		-			-		-		-		74			-			74
Deemed dividend related to the conversion of preferred stock		-			-		-			-		-		-		(74	)		-			(74	)
Net loss		-			-		-			-		-		-		-			(2,438	)		(2,438	)
Balance as of September 30, 2020		26		$	-		51		$	-		24,551,059	$	246	$	266,665		$	(239,375	)	$	27,536

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX Technologies, Inc.

Condensed Consolidated Statements of Cash Flows - Unaudited

(in thousands)

	Nine Months Ended September 30,
	2020			2019
Cash Flow From Operating Activities
Net loss	$	(5,296	)	$	(3,805	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		54			79
Amortization of right of use asset		310			264
Amortization of intangible assets		4			4
Non-cash interest income		(242	)		(344	)
Stock based compensation		29			2
Change in fair value of derivative liabilities		(1,750	)		(754	)
Offering Costs		325			-
Bad debt expense		-			(3	)
Changes in operating assets and liabilities:
Trade accounts receivable		87			154
Prepaid expenses and other current assets		(73	)		33
Inventories		104			(35	)
Accounts payable and accrued liabilities		(353	)		83
Payments on operating lease liability		(254	)		(557	)
Net cash used in operating activities		(7,055	)		(4,879	)
Cash Flows From Investing Activities
Purchase of property and equipment		(151	)		(141	)
Proceeds from notes receivable, net of imputed interest		1,528			1,111
Net cash provided by investing activities		1,377			970
Cash Flows From Financing Activities
Proceeds from issuance of warrant derivative liabilities		6,328			103
Proceeds from issuance of common stock, net of fees		20,015			1,285
Proceeds from issuance of preferred stock, net of fees		3,112			-
Proceeds from issuance of common stock in connection with exercise of warrants		1,109			-
Proceeds from issuance of debt		406			-
Principal payments on debt		(29	)		-
Net cash provided by financing activities		30,941			1,388
Net increase (decrease) in cash and cash equivalents		25,263			(2,521	)
Cash and cash equivalents at beginning of period		1,787			5,447
Cash and cash equivalents at end of period	$	27,050		$	2,926

Noncash Investing and Financing Activities
Reduction of derivative liability due to exercise of warrants	$	3,197		$	44
Change in par value due to conversion of preferred stock to common stock		65			-
Issuance of Common Stock for the Cashless Exercise of Warrants		35			-
Right-of-use assets and assumption of operating lease liability		-			2,704
Supplemental Cash Flow Information
Cash paid for interest	$	2		$	2

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX TECHNOLOGIES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization and Summary of Significant Accounting Policies

Organization

SINTX Technologies, Inc. (“SINTX” or “the Company”) was incorporated in the state of Delaware on December 10, 1996. SINTX is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride material and components in its FDA registered and ISO 13485:2016 certified facility. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. The Company’s products are primarily sold in the United States.

Reverse Stock Split

On July 26, 2019 the Company effected a 1 for 30 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock shares, equivalents, and per-share amounts for all periods presented in these condensed financial statements have been adjusted retroactively to reflect the reverse stock split.

Basis of Presentation

These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company. In May 2020, the Company dissolved its wholly owned subsidiary ST Sub, Inc. At the time of dissolution the subsidiary had no assets, liabilities, equity, or operations. The financial statements after May 8, 2020, are not consolidated.

SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 26, 2020. The results of operations for the nine months ended September 30, 2020, are not necessarily indicative of the results to be expected for the year ending December 31, 2020. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2019.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. As of September 30, 2020, the most significant estimates relate to inventory, long-lived and intangible assets, the liability for preferred stock and common stock warrants, and the derivative liabilities.

Liquidity and Capital Resources

The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements.

For the nine months ended September 30, 2020 and 2019, the Company incurred a net loss of $5.3 million and $3.8 million, respectively, and used cash in operations of $7.1 million and $4.9 million, respectively. The Company had an accumulated deficit of $239 million and $234 million as of September 30, 2020 and December 31, 2019, respectively. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operations or obtain additional financing is uncertain.

The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering in February 2014. On February 6, 2020, the Company closed on a rights offering to its stockholders of units, consisting of convertible preferred stock and warrants, for gross proceeds of $9.4 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company of approximately $1.2 million. Additionally, during the period of June 2020 through August 2020, the Company closed four registered direct offerings of shares of its common stock, priced at-the-market under Nasdaq rules, resulting in the issuance of a total of 11,015,000 shares of its common stock for gross proceeds of approximately $20.9 million, before considering issuance costs of approximately $1.6 million (see Note 8).

During the year ended December 31, 2019, the Company entered into an at-the-market (ATM) equity distribution agreement in which the Company may sell, from time to time, shares of common stock having an aggregate offering price of up to $2.5 million. The Company sold 527,896 shares during the year ended December 31, 2019, raising approximately $1.7 million before deducting fees to the placement agent and other offering expenses of approximately $0.2 million. During the nine month period ending September 30, 2020, the Company sold 354,500 shares of common stock, raising approximately $0.8 million deducting fees to the placement agent and other offering expenses of approximately $0.034 million. As of September 30, 2020, no funding capacity is available under the ATM. (see Note 8).

On October 1, 2018, the Company sold the retail spine business to CTL Medical. The sale included a $6 million noninterest bearing note receivable payable over a 36-month term. The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable to occur October 1, 2021. The Company expects cash flows of approximately $2.5 million for the remaining thirteen months.

Management has concluded that together with its existing capital resources and payments on the note receivable from the sale of the Spine business will be sufficient to fund operations for at least the next 12 months, or through November 2021. In the financial statements for the year ended December 31, 2019, the Company concluded substantial doubt existed for the Company to continue as a going concern. Beginning with the period ended March 31, 2020, the Company’s position changed as a result of the capital raises outlined in Note 8.

Risks Related to COVID-19 Pandemic

The recent outbreak of COVID-19 originated in Wuhan, China, in December 2019 and has since spread to multiple countries, including the United States and several European countries. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which we rely.

New Accounting Pronouncements Not Yet Adopted

The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements.

2. Basic and Diluted Net Income (Loss) per Common Share

Basic net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period that are determined to be dilutive. Common stock equivalents are primarily comprised of preferred stock and warrants for the purchase of common stock. For the three months ended September 30, 2020, there is no difference in the number of shares and net loss used to calculate basic and diluted shares outstanding because their effect would have been anti-dilutive. The Company had potentially dilutive securities, totaling approximately 1.6 million and 0.5 million as of September 30, 2020 and 2019, respectively.

Below are basic and diluted loss per share data for the three months ended September 30, 2020, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities		Diluted Calculation
Numerator:
Net loss	$	(2,437	)	$	-	$	(2,437	)
Deemed dividend and accretion of a discount		(74	)		-		(74	)
Net loss attributable to common stockholders	$	(2,511	)	$	-	$	(2,511	)

Denominator:
Number of shares used in per common share calculations:		22,774,263			-		22,774,263

Net loss per common share:
Net loss	$	(0.11	)	$	-	$	(0.11	)
Deemed dividend and accretion of a discount		-			-		-
Net loss attributable to common stockholders	$	(0.11	)	$	-	$	(0.11	)

Below are basic and diluted loss per share data for the nine months ended September 30, 2020, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(5,296	)	$	(2,073	)	$	(7,369	)
Deemed dividend and accretion of a discount		(9,565	)		-			(9,565	)
Net loss attributable to common stockholders	$	(14,861	)	$	(2,073	)	$	(16,934	)

Denominator:
Number of shares used in per common share calculations:		13,671,866			1,422,410			15,094,276

Net income (loss) per common share:
Net loss	$	(0.39	)	$	(0.10	)	$	(0.49	)
Deemed dividend and accretion of a discount		(0.70	)		0.07			(0.63	)
Net income (loss) attributable to common stockholders	$	(1.09	)	$	(0.03	)	$	(1.12	)

Below are basic and diluted loss per share data for the three months ended September 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(1,446	)	$	(144	)	$	(1,590	)
Deemed dividend and accretion of a discount		(345	)		-			(345	)
Net loss attributable to common stockholders	$	(1,791	)	$	(144	)	$	(1,935	)

Denominator:
Number of shares used in per common share calculations:		2,127,293			-			2,127,293

Net loss per common share:
Net loss	$	(0.68	)	$	(0.07	)	$	(0.75	)
Deemed dividend and accretion of a discount		(0.16	)		-			(0.16	)
Net loss attributable to common stockholders	$	(0.84	)	$	(0.07	)	$	(0.91	)

Below are basic and diluted loss per share data for the nine months ended September 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(3,805	)	$	(753	)	$	(4,558	)
Deemed dividend and accretion of a discount		(2,703	)		-			(2,703	)
Net loss attributable to common stockholders	$	(6,508	)	$	(753	)	$	(7,261	)

Denominator:
Number of shares used in per common share calculations:		1,269,106			-			1,269,106

Net loss per common share:
Net loss	$	(3.00	)	$	(0.59	)	$	(3.59	)
Deemed dividend and accretion of a discount		(2.13	)		-			(2.13	)
Net loss attributable to common stockholders	$	(5.13	)	$	(0.59	)	$	(5.72	)

3. Inventories

Inventories consisted of the following (in thousands):

	September 30, 2020		December 31, 2019
Raw materials	$	461	$	533
WIP		72		106
Finished Goods		2		-
	$	535	$	639

As of September 30, 2020, inventories totaling approximately $0.1 million and $0.5 million were classified as current and long-term, respectively. Inventories classified as current represent the carrying value of inventories as of September 30, 2020, that management estimates will be sold by September 30, 2021.

4. Intangible Assets

Intangible assets consisted of the following (in thousands):

	September 30, 2020			December 31, 2019
Trademarks	$	50		$	50
Less: accumulated amortization		(13	)		(9	)
	$	37		$	41

Amortization expense for the nine months ended September 30, 2020, was approximately $4.0 thousand. Amortization expense for the nine months ended September 30, 2019, was approximately $4.0 thousand.

5. Fair Value Measurements

Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis

The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:

	Level 1 -	quoted market prices for identical assets or liabilities in active markets.

	Level 2 -	observable prices that are based on inputs not quoted on active markets but corroborated by market data.

	Level 3 -	unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

The Company classifies assets and liabilities measured at fair value in their entirety based on the lowest level of input that is significant to their fair value measurement. No financial assets were measured on a recurring basis as of September 30, 2020 and December 31, 2019. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of September 30, 2020 and December 31, 2019 (in thousands):

	Fair Value Measurements as of September 30, 2020
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	1,600	$	1,600

	Fair Value Measurements as of December 31, 2019
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	220	$	220

The Company did not have any transfers of assets and liabilities between any levels of the fair value measurement hierarchy during the nine months ended September 30, 2020 and 2019 (in thousands).

	Common Stock Warrants
Balance as of December 31, 2018	$	(1,566	)
Change in fair value		754
Exercise of warrants		44
Other, net		(1	)
Balance as of September 30, 2019	$	(769	)

Balance as of December 31, 2019	$	(220	)
Issuance of derivatives		(6,328	)
Change in fair value		1,750
Exercise of warrants		3,197
Other, net		1
Balance as of September 30, 2020	$	(1,600	)

Common Stock Warrants

The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. As of September 30, 2020, and December 31, 2019, the derivative liability was calculated using the Monte Carlo Simulation valuation.

The assumptions used in estimating the common stock warrant liability as of September 30, 2020 and December 31, 2019 were as follows:

	September 30, 2020			December 31, 2019
Weighted-average risk-free interest rate		0.16%-0.28	%		1.62	%
Weighted-average expected life (in years)		2.61-4.36			3.4
Expected dividend yield		-	%		-	%
Weighted-average expected volatility		139.17%-160.7	%		64	%

Other Financial Instruments

The Company’s recorded values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The recorded value of debt approximates the fair value as the interest rate approximates market interest rates.

6. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	September 30, 2020		December 31,2019
Payroll and related expense	$	646	$	589
Resterilization and repackaging costs		52		392
Other		248		285
	$	946	$	1,266

7. Debt

Equipment Loan

In September 2019, the Company entered into a debt arrangement with a finance company to purchase equipment. The debt balance was paid in full during the third quarter 2020.

PPP Loan

On April 28, 2020, the Company received funding under a Paycheck Protection Program (“PPP”) loan (the “PPP Loan”) from First State Community Bank (the “Lender”). The principal amount of the PPP Loan is $0.391 million. The PPP was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (the “SBA”). The PPP Loan has a two-year term, maturing on April 28, 2022. The term may be extended to five-years if the Lender and we agree to do so. The interest rate on the PPP Loan is 1.0% per annum. Principal and interest are payable in 18 monthly installments, beginning on November 28, 2020, until maturity with respect to any portion of the PPP Loan which is not forgiven as described below. The Company did not provide any collateral or guarantees for the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan. The PPP Loan provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects. The Company is permitted to prepay or partially prepay the PPP Loan at any time with no prepayment penalties. The PPP Loan may be partially or fully forgiven if the Company complies with the provisions of the CARES Act, including the use of PPP Loan proceeds for payroll costs, rent, utilities and other expenses, provided that such amounts are incurred during a 24-week period that commenced on April 28, 2020 and at least 60% of any forgiven amount has been used for covered payroll costs as defined by the CARES Act. Any forgiveness of the PPP Loan will be subject to approval by the SBA and the Lender and will require the Company to apply for such treatment in the future.

8. Equity

2020 Rights Offering

During February 2020, the Company closed on a rights offering capital raise wherein the Company’s holders of common stock, Series C Preferred Stock, and certain outstanding warrants on the date of record, obtained, at no charge, non-transferable subscription rights to purchase units (“Units”). Each Unit consisted of one share of Series C Convertible Preferred Stock (“Preferred Stock”) and 675 warrants to purchase common stock (“Warrants”). Each Unit sold for $1,000. Each share of the Preferred Stock is convertible, at the Company’s option at any time on or after the first anniversary of the expiration of the rights offering or at the option of the holder at any time, into a number of shares of our common stock equal to the quotient of the stated value of the Preferred Stock ($1,000) divided by the Conversion Price ($1.4814 per share). Each Warrant is exercisable for one share of our common stock at an exercise price of $1.50 per share from the date of issuance through its expiration five years from the date of issuance. The Warrants also contain a cashless exercise provision that allows the holder to receive 70% of the common stock otherwise available under the warrant to the holder electing the cashless exercise provision. The Company issued 9,440 Units, which includes 6,372,000 Warrants exercisable into shares of our common stock and preferred shares that are convertible into 6,372,350 shares of Common Stock, for gross proceeds of $9.4 million.

The Company raised $9.4 million, before consideration of issuance costs, associated with the issuance of the Units, with $3.1 million allocated to the preferred stock (with no issuance costs allocated to the preferred stock) and $5.1 million, net of issuance costs of approximately $1.2 million, allocated to the warrants. In association with the warrants that were recorded as a derivative liability, the Company immediately expensed approximately all $1.2 million of the issuance costs.

During the nine months ended September 30, 2020, Series B Convertible Preferred stockholders of the Company converted 223 shares of Series B Convertible Preferred Stock into 165,586 shares of common stock, and Series C Convertible Preferred stockholders of the Company converted 9,389 shares of Series C Convertible Preferred Stock into 6,337,930 shares of common stock.

Also, during the nine months ended September 30, 2020, holders of Warrants electing to use the cashless exercise option exercised 5,006,475 warrants, which resulted in the issuance of 3,504,535 shares of common stock. During the same period of time, holders of Warrants electing to exercise warrants for cash exercised 739,618 warrants, which resulted in the issuance of 739,618 shares of common stock, and the receipt of $1.1 million of cash.

2020 Registered Direct Offerings

During June 2020, the Company closed two registered direct offerings of shares of its common stock, priced at-the-market under Nasdaq rules, resulting in the issuance of a total of 6,100,000 shares of its common stock for gross proceeds of approximately $9.6 million, before considering issuance costs of approximately $0.8 million. On June 23, 2020, the Company entered into a Share Purchase Agreement with certain institutional purchasers, pursuant to which the Company agreed to issue and sell to the purchasers, in a registered direct offering, an aggregate of 3,700,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $1.50 per share for aggregate gross proceeds to the Company of approximately $5.5 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company. Following the initial registered direct offering, on June 26, 2020, the Company entered into another Share Purchase Agreement with certain institutional purchasers pursuant to which the Company offered to the purchasers, in a registered direct offering, an aggregate of 2,400,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $1.72 per share for aggregate gross proceeds to the Company of approximately $4.1 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company.

On July 16, 2020, the Company entered into a Share Purchase Agreement with certain institutional purchasers, pursuant to which the Company agreed to issue and sell to the purchasers, in a registered direct offering, an aggregate of 1,500,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $2.00 per share for aggregate gross proceeds to the Company of $3.0 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company.

On August 4, 2020, the Company entered into a Share Purchase Agreement with certain institutional purchasers, pursuant to which the Company agreed to issue and sell to the purchasers, in a registered direct offering, an aggregate of 3,415,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $2.40 per share for aggregate gross proceeds to the Company of $8.2 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company.

2019 ATM Stock Offerings

On June 4, 2019, the Company entered into an Equity Distribution Agreement, (the “Distribution Agreement”), with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell from time to time, shares of its common stock, having an aggregate offering price of up to $1.6 million through Maxim, as agent (the “ATM Offering”). On September 12, 2019, the Company entered into an amendment to the Distribution Agreement with Maxim, which increased the maximum aggregate offering price of the shares of the Company’s common stock from $1.6 million to $2.5 million. Subject to the terms and conditions of the Distribution Agreement, Maxim will use its commercially reasonable efforts to sell the shares from time to time, based on the Company’s instructions. The Company has no obligation to sell any of the shares and may at any time suspend offers under the Distribution Agreement. The Offering will terminate upon the earlier of (i) the sale of Shares having an aggregate offering price of $2.5 million, (ii) the termination of the Distribution Agreement by either Maxim or the Company upon the provision of fifteen (15) days written notice, or (iii) September 12, 2020. The Company agrees to pay Maxim a transaction fee at a fixed rate of 4.25% of the gross sales price of shares sold under the Distribution Agreement and agreed to provide indemnification and contribution to Maxim with respect to certain liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. During the year ended December 31, 2019, the Company raised approximately $1.7 million before deducting fees to the placement agent and other offering expenses of approximately $0.2 million, through the issuance of 527,896 shares of common stock under the Distribution Agreement with Maxim. During the nine month period ending September 30, 2020, the Company sold 354,500 shares of common stock, raising approximately $0.8 million before deducting issuance fees of approximately $0.034 million. As of September 30, 2020, no funding capacity is available under the ATM.

9. Stock-Based Compensation

During the three months ended September 30, 2020 the shareholders approved the 2020 Equity Incentive Plan. The 2020 Plan provides for the grant of nonqualified stock options, incentive stock options, restricted stock, restricted stock units, stock appreciation rights (SARs), and performance share awards to employees, officers, consultants, advisors, non-employee directors and independent contractors designated by either the board of directors of the Company or if so authorized by the board of directors, the Compensation Committee (the “Committee”) of the Board of Directors. Under the 2020 Plan, the maximum number of shares of common stock which may be issued, subject to adjustment as described below, is 1,902,520 shares of common stock, which includes 2,520 shares that have been rolled over from our 2012 Plan, as amended.

A summary of the Company’s outstanding stock option activity for the nine months ended September 30, 2020 is as follows:

	Options		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Intrinsic Value
As of December 31, 2019		377	$	7,446.69		5.3	$	-
Granted		515,017		0.47		10.0		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Expired		-		-		-		-
As of September 30, 2020		515,394	$	5.90		9.6	$	746,774
Exercisable as of September 30, 2020		377	$	7,446.69		4.6	$	-

The Company estimates the fair value of each stock option on the grant date using the Black-Scholes-Merton valuation model, which requires several estimates including an estimate of the fair value of the underlying common stock on grant date. The expected volatility was based on an average of the historical volatility the Company. The expected term was calculated utilizing the simplified method. The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the option. The following weighted average assumptions were used in the calculation to estimate the fair value of options granted to employees during the nine months ended September 30, 2020.

	Nine Months Ended
	September 30, 2020
Weighted-average risk-free interest rate		0.34	%
Weighted-average expected life (in years)		10.0
Expected dividend yield		-	%
Weighted-average expected volatility		129.69	%

Unrecognized stock-based compensation as of September 30, 2020 is as follows (in thousands):

			Weighted Average
	Unrecognized Stock-Based		Remaining of Recognition
	Compensation		(in years)
Stock options	$	204		2.6

10. Commitments and Contingencies

The Company has executed agreements with certain executive officers of the Company which, upon the occurrence of certain events related to a change in control, call for payments to the executives up to three times their annual salary and accelerated vesting of previously granted stock options.

From time to time, the Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. Management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s financial position, operating results or cash flows.

11. Note Receivable

On October 1, 2018, the Company completed the sale of its retail spine business to CTL Medical. The sale included a $6 million noninterest bearing note receivable. The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable on October 1, 2021. The note receivable includes an imputed interest rate of 10%, which totaled $915,725 as of October 31, 2018, and has a 36-month amortization. As of September 30, 2020, the net carrying value of the note receivable was approximately $2.4 million, with expected cash proceeds of $2.5 million.

12. Discontinued Operations

The Company and CTL Medical entered in an asset purchase agreement on October 1, 2018, whereby CTL Medical agreed to acquire all of the Company’s commercial spine business for total consideration of $8.5 million, which includes a $6.0 million (including interest) note receivable and CTL Medical’s assumption of the Company’s $2.5 million related party note payable to North Stadium. As a result of the closing, CTL Medical is now the exclusive owner of SINTX’s portfolio of metal and silicon nitride spine products, which are presently sold under the brand names of Taurus, Preference, and Valeo, with access to future silicon nitride spine technologies. The Company has agreed to pay the cost, if any, to re-sterilize and re-package select silicon nitride spinal inventories sold to CTL Medical if the sterilization date expires prior to CTL Medical selling the inventories to a third-party customer. This agreement extends for a total of 24 months, ending on September 30, 2020. The Company estimates the sterilization and repackaging cost to approximate $0.1 million at September 30, 2020. Manufacturing, R&D, and all intellectual property related to the core, non-spine, biomaterial technology of silicon nitride remains with the Company in Salt Lake City. The Company will serve as CTL’s exclusive OEM provider of silicon nitride products.

13. Leases

The Company leases office, warehouse and manufacturing space under a single operating lease. On June 7, 2019, the lease was amended to extend the rental period through 2024 and reduce the amount of space leased from 54,428 square feet to 29,732 square feet. The new rent was effective January 1, 2020. The amended lease has two five-year extension options. As of September 30, 2020, the operating lease right-of-use asset totaled approximately $2.0 million and the operating lease liability totaled approximately $2.0 million. Non-cash operating lease expense during the nine months ended September 30, 2020, totaled approximately $0.3 million. As of September 30, 2020, the weighted-average discount rate for the Company’s operating lease was 6.5%.

Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. The Company accounts for lease components separately from the non-lease components. The depreciable life of the assets and leasehold improvements are limited by the expected lease term.

Operating lease future minimum payments together with the present values as of September 30, 2020, are summarized as follows:

Years Ending December 31,	September 30, 2020
2020	$	124
2021		513
2022		528
2023		544
2024		561
Thereafter		-
Total future minimum lease payments		2,270
Less amounts representing interests		(297	)
Present value of lease liability		1,973

Current-portion of operating lease liability		393
Long-term portion operating lease liability	$	1,580

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements for the year ended December 31, 2019 and the notes thereto, along with Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2019, filed separately with the U.S. Securities and Exchange Commission. This discussion and analysis contains forward-looking statements based upon current beliefs, plans, expectations, intentions and projections that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2019, and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q and in other filings with the Securities and Exchange Commission we may make from time-to-time.

Overview

We are an advanced materials company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. We believe that silicon nitride has a superb combination of properties that make it ideally suited for long-term human implantation. Other biomaterials are based on bone grafts, metal alloys, and polymers, all of which have well-known practical limitations and disadvantages. In contrast, silicon nitride has a legacy of success in the most demanding and extreme industrial environments. As a human implant material, silicon nitride offers bone ingrowth, resistance to bacterial and viral infection, ease of diagnostic imaging, resistance to corrosion, and superior strength and fracture resistance, among other advantages, all of which claims are validated in our large and growing inventory of peer-reviewed, published literature reports.

We recently received positive testing results from an independent study that demonstrate the potential anti-viral properties of our silicon nitride. The results suggest that silicon nitride may be useful in the reduction of the spread of COVID-19. The study results demonstrated that our unique grade of silicon nitride inactivates the SARS-CoV-2 virus within a minute after exposure and has the potential to decrease the risk of viral disease spread on surfaces. Studies have shown that coronavirus spreads between humans when an infected person coughs or sneezes. Also, the virus can remain active on a variety of commonly touched surfaces for hours to days. We believe that by incorporating our unique composition of silicon nitride into products such as face masks, and personal protective equipment, it is possible to manufacture surfaces that inactivate viral particles, thereby limiting the spread of the disease. We envision incorporating our silicon nitride into high-contact surfaces such as medical equipment, screens, countertops, and doorknobs in locations where viral persistence is a concern, such as homes, casinos, and cruise ships. We believe this anti-viral discovery will open many new opportunities for us. In composites, coatings, and mixtures, silicon nitride has maintained its antibacterial and osteogenic properties, even at small fractions. We believe that incorporating our material into a variety of commonly touched surfaces may discourage viral spread, and contribute to global health by reducing the risk of disease. We believe that our versatile silicon nitride manufacturing expertise positions us favorably to introduce new and innovative devices in the medical and non-medical fields.

We also believe that we are the first and only company to commercialize silicon nitride medical implants. Prior to October 1, 2018, we designed, manufactured and commercialized silicon nitride products for our own behalf in the spine implant market. Over 35,000 of our spinal implants manufactured with silicon nitride have been implanted into patients, with an excellent safety record. On October 1, 2018, we sold our spine implant business to CTL Medical and now manufacture spine implants made with silicon nitride for CTL Medical. Prior to selling our spine implant business to CTL Medical, we had received 510(k) regulatory clearance in the United States, a CE mark in Europe, ANVISA approval in Brazil, and ARTG and Prostheses approvals in Australia for a number of silicon nitride spine implant products designed for spinal fusion surgery. Spine implant products manufactured by us from silicon nitride are currently marketed and sold by CTL Medical under the Valeo® brand to surgeons and hospitals in the United States and to selected markets in Europe and South America. These implants are designed for use in cervical (neck) and thoracolumbar (lower back) spine surgery. We are collaborating with CTL Medical to establish commercial partners in other parts of the world and also working with other partners to obtain regulatory approval for silicon nitride implants in Japan.

The sale of our spine implant business to CTL Medical enables us to now focus on our core competencies. These include research and development of silicon nitride and the design and manufacture of medical and nonmedical products manufactured from silicon nitride and other ceramic materials for our own account and in collaboration with other medical device manufacturers. We are targeting original equipment manufacturer (“OEM”) – including CTL Medical - and private label partnerships in order to accelerate adoption of silicon nitride in future markets such as coating products with silicon nitride, hip and knee replacements, dental and maxillofacial implants, extremities, trauma, bearings, automotive and aerospace components, cutting tools, and a wide range of antipathogenic applications. Existing biomaterials, based on plastics, metals, and bone grafts have well-recognized limitations that we believe are addressed by silicon nitride.

We believe that silicon nitride addresses many of the biomaterial-related limitations in medical related fields such as hip and knee replacements, dental and maxillofacial implants, sports medicine, extremities, and trauma surgery. We further believe that the inherent material properties of silicon nitride, and the ability to formulate the material in a variety of compositions, combined with precise control of the surface properties of the material, opens up a number of commercial opportunities across orthopedic surgery, neurological surgery, maxillofacial surgery, other medical disciplines, as well as commodity items such as industrial fasteners, bushings, and valves to addressing more complex demands of hypersonic missile radomes, aerospace, air-conditioning systems, beverage dispensers, touch-screen glass, and agribusiness fungicides. In the second quarter, the Company shipped three prototype orders of industrial products totaling $7 thousand.

Components of our Results of Operations

We manage our business within one reportable segment, which is consistent with how our management reviews our business, makes investment and resource allocation decisions and assesses operating performance.

Product Revenue

We derive our product revenue primarily from the manufacture and sale of spinal fusion products used in the treatment of spine disorders to CTL Medical, with whom we entered into a 10-year exclusive sales agreement in October 2018. We are currently pursuing other sales opportunities for silicon nitride products outside the spinal fusion application and have shipped new orders for these products. We generally recognize revenue from sales where control transfers at a point in time as the title and risk of loss passes to the customer, which is at the time the product is shipped. In general, our customer does not have rights of return or exchange.

Prior to the occurrence of the COVID-19 pandemic, we believed that our product revenue would increase as CTL Medical increased sales of silicon nitride spinal fusion products, as we secured other opportunities to manufacture third party products with silicon nitride, and as we continued to introduce new products into the market. We now expect COVID-19 to adversely impact product revenue from silicon nitride spinal fusion products for the remainder of 2020, and potentially longer.

Cost of Revenue

The expenses that are included in cost of revenue include all in-house manufacturing costs for the products we manufacture.

Gross Profit

Our gross profit measures our product revenue relative to our cost of revenue. We expect our gross profit percentage to decrease as we expand the penetration of our silicon nitride technology platform through OEM and private label partnerships, which offer additional avenues for the adoption of silicon nitride. Prior to the sale of our retail spine business, our revenues and gross profits were based on our retail sales. With the focus on OEM and private label partnerships, the margins are lower, thus causing the decrease in our gross profit percentage.

Research and Development Expenses

Our research and development costs are expensed as incurred. Research and development costs consist of engineering, product development, clinical trials, test-part manufacturing, testing, developing and validating the manufacturing process, manufacturing, facility and regulatory-related costs. Research and development expenses also include employee compensation, employee and non-employee stock-based compensation, supplies and materials, consultant services, and travel and facilities expenses related to research and development activities.

We expect to incur additional research and development costs as we continue to develop new spinal fusion products, product candidates for total joint replacements, dental applications, antipathogenic products, and other products which may increase our total research and development expenses.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation for certain members of our executive team and other personnel employed in finance, compliance, administrative, information technology, customer service, executive and human resource departments. General and administrative expenses also include other expenses not part of the other cost categories mentioned above, including facility expenses and professional fees for accounting and legal services.

RESULTS OF OPERATIONS

The following is a tabular presentation of our unaudited condensed consolidated operating results for the three months ended September 30, 2020 and 2019 (in thousands):

	Three Months Ended September 30,						$			%			Nine Months Ended September 30,						$			%
	2020			2019			Change			Change			2020			2019			Change			Change
Product revenue	$	66		$	173		$	(107	)		-62	%	$	478		$	437		$	41			9	%
Cost of revenue		53			151			(98	)		-65	%		382			364			18			5	%
Gross profit		13			22			(9	)		-41	%		96			73			23			32	%
Gross profit %		20	%		13	%		7	%		54	%		20	%		17	%		3	%		20	%

Operating expenses:
Research and development		1,432			869			563			65	%		3,494			2,557			937			37	%
General and administrative		827			714			113			16	%		2,418			2,166			252			12	%
Sales and marketing		182			139			43			31	%		450			303			147			49	%
Total operating expenses		2,441			1,722			719			42	%		6,362			5,026			1,336			27	%
Loss from operations		(2,428	)		(1,700	)		(728	)		43	%		(6,266	)		(4,953	)		(1,313	)		27	%
Other income (expense)		(9	)		254			(263	)		-104	%		970			1,148			(178	)		-16	%
Net loss before taxes		(2,437	)		(1,446	)		(991	)		69	%		(5,296	)		(3,805	)		(1,491	)		39	%
Provision for income taxes		-			-			-						-			-			-
Net loss	$	(2,437	)	$	(1,446	)	$	(991	)		69	%	$	(5,296	)	$	(3,805	)	$	(1,491	)		39	%

Product Revenue

For the three months ended September 30, 2020, total product revenue was $0.066 million as compared to $0.173 million in the same period 2019, a decrease of $0.107 million, or -62%. This decrease was due to reduction in orders from CTL Amedica.

For the nine months ended September 30, 2020, total product revenue was $0.478 million as compared to $0.437 million in the same period 2019, an increase of $0.041 million, or 9%. This increase was primarily due to an increase in orders from CTL Amedica and to some non-medical orders.

Cost of Revenue and Gross Profit

For the three months ended September 30, 2020, our cost of revenue decreased $0.098 million, or -65%, as compared to the same period in 2019. Gross profit decreased $0.009 million or -41%. Both decreases are primarily due to decrease in product revenue, and the associated decrease in costs of goods sold. Gross profit margin percentage totaled 20% and 13% for the three months ended September 30 for 2020 and 2019, respectively.

For the nine months ended September 30, 2020, our cost of revenue increased $0.018 million, or 5%, as compared to the same period in 2019. Gross profit increased $0.023 million or 32%. Both increases correspond with the increase in product revenue, and the associated increase in costs of goods sold. Gross profit margin percentage totaled 20% and 17% for the nine months ended September 30 for 2020 and 2019, respectively.

Research and Development Expenses

For the three months ended September 30, 2020, research and development expenses increased $0.6 million, or 65%, as compared to the same period in 2019. This increase was primarily attributable to an increase in R&D wages for new personnel, new equipment, and outside research activities related to testing the anti-viral properties of silicon nitride to support the Company’s strategic objective of developing new technologies and related products.

For the nine months ended September 30, 2020, research and development expenses increased $0.9 million, or 37%, as compared to the same period in 2019. This increase was primarily attributable to an increase in R&D wages for new personnel and outside research activities related to testing the anti-viral properties of silicon nitride to support the Company’s strategic objective of developing new technologies and related products.

General and Administrative Expenses

For the three months ended September 30, 2020, general and administrative expenses increased $0.1 million, or 16%, as compared to the same period in 2019. This increase is primarily due to the increase in franchise taxes, investor relations costs, and an increase in wages for new personnel.

For the nine months ended September 30, 2020, general and administrative expenses increased $0.3 million, or 12%, as compared to the same period in 2019. This increase is primarily due to the increase in franchise taxes and an increase in wages for new personnel.

Sales and Marketing Expenses

For the three months ended September 30, 2020, sales and marketing expenses increased $0.04 million, or 31%, as compared to the same period in 2019. This increase was primarily attributable to an increase in marketing activities to generate interest in and exposure to the Company’s potential new product lines.

For the nine months ended September 30, 2020, sales and marketing expenses increased $0.1 million, or 49%, as compared to the same period in 2019. This increase was primarily attributable to an increase in sales and marketing wages for new personnel and an increase in marketing activities to generate interest in and exposure to the Company’s potential new product lines.

Other Income, Net

For the three months ended September 30, 2020, other income decreased $0.3 million, or 104%, as compared to the same period in 2019. This decrease was primarily due to the unfavorable change in the fair value of the derivative liabilities in the amount of $0.4 million offset by other miscellaneous other income items of approximately $0.1 million.

For the nine months ended September 30, 2020, other income decreased $0.2 million, or 16%, as compared to the same period in 2019. This decrease was primarily due to the decrease in income due to offering costs of $1.2 million associated with the February 2020 rights offering and interest income of $0.1 million offset by the change in the fair value of the derivative liabilities in the amount of $1.0 million and the gain in the reduction of the accrued sterilization of $0.1 million.

Liquidity and Capital Resources

The Company is actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of our silicon nitride material are not well known, and we believe the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications. For instance, we recently received positive testing results from an independent study that demonstrate the potential anti-viral properties of our silicon nitride. We believe that we may be able to apply our silicon nitride powder to personal protection products, such as face masks, gowns and gloves, resulting in inactivation of viruses that come into contact with the items.

The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering in February 2014. On February 6, 2020, the Company closed on a rights offering to its stockholders of units, consisting of convertible preferred stock and warrants, for gross proceeds of $9.4 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company. Additionally, during the period of June 2020 through August 2020, the Company closed four registered direct offerings of shares of its common stock, priced at-the-market under Nasdaq rules, resulting in the issuance of a total of 11,015,000 shares of its common stock for gross proceeds of approximately $20.9 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company.

During the year ended December 31, 2019, the Company entered into an ATM equity distribution agreement in which the Company may sell, from time to time, shares of common stock having an aggregate offering price of up to $2.5 million. The Company sold 527,896 shares during the year ended December 31, 2019, raising approximately $1.7 million before considering issuance costs. During the nine month period ending September 30, 2020, the Company sold 354,500 shares of common stock, raising approximately $0.8 million before considering issuance costs. As a result of the sales during the first half of 2020 there are no longer any funds available to the Company under the ATM.

Risks Related to COVID-19 Pandemic

Cash Flows

The following table summarizes, for the periods indicated, cash flows from operating, investing and financing activities (in thousands) – unaudited:

	Nine Months Ended September 30,
	2020			2019
Net cash used in operating activities	$	(7,055	)	$	(4,879	)
Net cash provided by investing activities		1,377			970
Net cash provided by financing activities		30,941			1,388
Net cash provided (used)	$	25,263		$	(2,521	)

Net Cash Used in Operating Activities

Net cash used in operating activities was $7.1 million during the nine months ended September 30, 2020, compared to $4.9 million used during the nine months ended September 30, 2019, an increase of $2.2 million. The increase in the net loss from operations, and related non-cash add backs to the net loss, was $2.0 million from 2020 when compared to 2019. The increase in cash used for operating activities during 2020 was primarily due to the $2.0 million mentioned above plus changes in the movement of working capital items during 2020 as compared to the same period in 2019 as follows: a $0.4 million increase in cash used in accounts payable, and a $0.1 million increase in cash used in prepaid expenses, offset by a $0.3 million decrease in cash payments on operation lease liability.

Net Cash Provided by Investing Activities

Net cash provided by investing activities increased by $0.4 million during the nine months ended September 30, 2020, as compared to the same period in 2019. This increase was primarily due to an increase in proceeds from notes receivable.

Net Cash Provided by Financing Activities

Net cash provided by financing activities was $30.9 million during the nine months ended September 30, 2020, compared to net cash provided by financing activities of $1.4 million during the same period in 2019. The $29.5 million increase was primarily attributable an increase in proceeds from rights offerings of $9.4 million, an increase in proceeds from issuance of common stock in the amount of $18.7 million, an increase in proceeds of $1.0 million from warrants exercised for cash, and $0.4 million increase from the issuance of debt.

Indebtedness

Equipment Loan

In September 2019, the Company entered into a debt arrangement with a finance company to purchase equipment. The debt balance was paid in full during the third quarter 2020 and as of September 30, 2020, totaled $0 thousand

PPP Loan

On April 28, 2020, the Company received funding under a Paycheck Protection Program (“PPP”) loan (the “PPP Loan”) from First State Community Bank (the “Lender”). The principal amount of the PPP Loan is $0.391 million. The PPP Loan has a two-year term, maturing on April 28, 2022. The term may be extended to five-years if the Lender and we agree to do so. The interest rate on the PPP Loan is 1.0% per annum. Principal and interest are payable in 18 monthly installments, beginning on November 28, 2020, until maturity with respect to any portion of the PPP Loan which is not forgiven as described below. The PPP Loan may be partially or fully forgiven if the Company complies with the provisions of the CARES Act, including the use of PPP Loan proceeds for payroll costs, rent, utilities and other expenses, provided that such amounts are incurred during a 24-week period that commenced on April 28, 2020 and at least 60% of any forgiven amount has been used for covered payroll costs as defined by the CARES Act. Any forgiveness of the PPP Loan will be subject to approval by the SBA and the Lender and will require the Company to apply for such treatment in the future.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as defined in Item 303(a)(4) of Regulation S-K.

Critical Accounting Policies and Estimates

A summary of our significant accounting policies and estimates is discussed in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in Note 1 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019. There have been no material changes to those policies for the nine months ended September 30, 2020. The preparation of the condensed financial statements in accordance with U.S. generally accepted accounting principles requires us to make judgments, estimates and assumptions regarding uncertainties that affect the reported amounts of assets and liabilities. Significant areas of uncertainty that require judgments, estimates and assumptions include the accounting for income taxes, contingencies, valuation of derivative liabilities, asset impairment and collectability of accounts receivable. We use historical and other information that we consider to be relevant to make these judgments and estimates. However, actual results may differ from those estimates and assumptions that are used to prepare our condensed financial statements.

New Accounting Pronouncements

No new accounting pronouncements have been adopted during the nine months ended September 30, 2020.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

This Report includes the certifications of our Chief Executive Officer and Principal Financial Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations referred to in those certifications.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed in the reports filed or submitted under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified by the Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act are properly recorded, processed, summarized and reported within the time periods required by the Commission’s rules and forms.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (principal executive officer and principal financial officer), of the effectiveness of the design and operation of these disclosure controls and procedures, as such term is defined in Exchange Act Rule 13a-15(e), as of September 30, 2020. Based on this evaluation, the Chief Executive Officer concluded that our disclosure controls and procedures were effective as of September 30, 2020, the end of the period covered by this Quarterly Report on Form 10-Q.

There were no changes in our internal control over financial reporting that occurred during the third quarter of 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

ITEM 1. LEGAL PROCEEDINGS

We are not aware of any pending or threatened legal proceeding against us that could have a material adverse effect on our business, operating results or financial condition. The medical device industry is characterized by frequent claims and litigation, including claims regarding patent and other intellectual property rights as well as improper hiring practices. As a result, we may be involved in various additional legal proceedings from time to time.

Item 1A. Risk Factors

Information regarding risk factors appears in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on March 26, 2020. There have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K, except as noted below.

We are subject to risks associated with the spread of the novel strain of coronavirus, or COVID-19.

Our operations expose us to risks associated with the spread of COVID-19, which has affected the regions in which we conduct our operations. COVID-19 has broadly affected the global economy, resulted in significant travel and work restrictions in many regions and has put a significant strain on healthcare resources. COVID-19 is having, and we expect it will continue to have, an impact on our operations and an impact on the operations of CTL Amedica, the sole customer for our spine implant products, our collaborators, potential collaborators, third-party contractors and other entities, including governments, governmental agencies, with which we interact. To date, the most significant effects on our business have been reductions in sales of products to CTL Amedica which will result in reduced product revenue, delays in in discussions with potential collaborators, OEM customers, certain research and development activities and that many of our employees work remotely. In the future, the economic impacts of the COVID-19 outbreak could affect our business directly or indirectly. The effects on our product sales to CTL Amedica, research, development, manufacturing and commercialization activities, will be dependent on, among other things, the severity and duration of the COVID-19 outbreak as well as the impact of the outbreak on our third-party manufacturers, suppliers, subcontractors and customers. While the ultimate impact of COVID-19 on our business is highly uncertain, any negative impacts that materialize could materially adversely affect our operations, financial performance and stock price. Any negative impacts of COVID-19, alone or in combination with others, could exacerbate risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019. The full extent to which the COVID-19 outbreak will negatively affect our operations, financial performance and stock price will depend on future developments that are highly uncertain and cannot be predicted, including the scope and duration of the outbreak and actions taken by governmental authorities and other third parties in response to the outbreak.

Our silicon nitride may not be effective in the reduction of the spread of COVID-19.

There is no guarantee that our silicon nitride will be effective in the reduction of the spread of COVID-19 by inactivating the SARS-CoV-2 virus or that we will be able to commercialize our silicon nitride for that purpose.

We may not be successful in utilizing silicon nitride in products

Although we have received positive results suggesting that it may be possible to utilize silicon nitride in products to help reduce the spread of COVID-19, there is no assurance that we will be able to integrate silicon nitride into products, or that even if we are able to do so, we will achieve positive results. Production of products for this purpose has not begun, and we may determine that it is not feasible to produce products in the desired manner, or that such products will decrease the viral disease spread on surfaces. In addition, there is significant competition from other companies trying to develop products to help treat the spread of COVID-19; many of these companies have greater resources than we do and we may not be able to successfully compete against them.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit Number	Exhibit Description	Filed Herewith	Incorporated by Reference herein from Form or Schedule	Filing Date	SEC File/ Reg. Number

10.1	Form of Share Purchase Agreement dated July 16, 2020		Form 8-K Exhibit 99.1	7/20/20	001-33624

10.2	Form of share Purchase Agreement dated August 4, 2020		Form 8-K Exhibit 99.1	8/06/20	001-33624

31.1	Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X

31.2	Certificate of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X

32	Certifications of the Chief Executive Officer and Principal Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X

101.INS	XBRL Instance Document	X

101.SCH	XBRL Taxonomy Extension Schema Document	X

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document	X

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document	X

101.LAB	XBRL Taxonomy Extension Label Linkbase Document	X

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document	X

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SINTX Technologies, Inc.

Date: November 16, 2020	/s/ B. Sonny Bal
	B. Sonny Bal
	Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, B. Sonny Bal, certify that:

1. I have reviewed this quarterly report on Form 10-Q of SINTX Technologies, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 16, 2020	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Chief Executive Officer

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, B. Sonny Bal, certify that:

1. I have reviewed this quarterly report on Form 10-Q of SINTX Technologies, Inc.;

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 16, 2020	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Chief Executive Officer and Principal Financial Officer

EX-32 4 ex32.htm

Exhibit 32

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of SINTX Technologies, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The quarterly report for the quarter ended September 30, 2020 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 16, 2020	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Chief Executive Officer

	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Principal Financial Officer

EX-101.INS 5 sint-20200930.xml XBRL INSTANCE FILE 0001269026 2020-01-01 2020-09-30 0001269026 us-gaap:TrademarksMember 2019-12-31 0001269026 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2019-12-31 0001269026 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2019-12-31 0001269026 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2019-12-31 0001269026 us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2019-12-31 0001269026 2019-12-31 0001269026 2020-09-30 0001269026 SINT:CommonStockWarrantsMember 2018-12-31 0001269026 us-gaap:CommonStockMember 2018-12-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001269026 us-gaap:RetainedEarningsMember 2018-12-31 0001269026 SINT:AssetPurchaseAgreementMember 2018-09-29 2018-10-02 0001269026 SINT:AssetPurchaseAgreementMember SINT:NoninterestBearingNoteReceivableMember 2018-09-29 2018-10-02 0001269026 SINT:AssetPurchaseAgreementMember SINT:RelatedPartyNotePayableMember 2018-09-29 2018-10-02 0001269026 2018-10-02 0001269026 2018-09-29 2018-10-02 0001269026 2018-10-31 0001269026 us-gaap:CommonStockMember 2019-12-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001269026 us-gaap:RetainedEarningsMember 2019-12-31 0001269026 SINT:CommonStockWarrantsMember 2019-12-31 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputOptionVolatilityMember 2019-12-31 0001269026 SINT:SeriesBConvertiblePreferredStockMember 2019-12-31 0001269026 2019-06-06 2019-06-07 0001269026 2019-06-07 0001269026 SINT:ATMEquityDistributionAgreementMember srt:MaximumMember 2019-01-01 2019-12-31 0001269026 SINT:ATMEquityDistributionAgreementMember 2019-01-01 2019-12-31 0001269026 2019-07-25 2019-07-26 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001269026 2019-09-30 0001269026 SINT:ATMEquityDistributionAgreementMember srt:MaximumMember 2019-06-03 2019-06-04 0001269026 SINT:ATMEquityDistributionAgreementMember srt:MinimumMember 2019-09-11 2019-09-12 0001269026 SINT:ATMEquityDistributionAgreementMember srt:MaximumMember 2019-09-11 2019-09-12 0001269026 SINT:ATMEquityDistributionAgreementMember 2020-09-12 0001269026 SINT:SeriesBConvertiblePreferredStockMember 2020-09-30 0001269026 SINT:SeriesCConvertiblePreferredStockMember 2020-09-30 0001269026 SINT:SeriesCConvertiblePreferredStockMember 2019-12-31 0001269026 2019-01-01 2019-09-30 0001269026 us-gaap:CommonStockMember 2020-09-30 0001269026 us-gaap:CommonStockMember 2019-09-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001269026 us-gaap:RetainedEarningsMember 2020-09-30 0001269026 us-gaap:RetainedEarningsMember 2019-09-30 0001269026 2018-12-31 0001269026 2019-06-30 0001269026 2020-02-05 2020-02-06 0001269026 SINT:ATMEquityDistributionAgreementMember 2020-01-01 2020-09-30 0001269026 us-gaap:TrademarksMember 2020-09-30 0001269026 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2020-09-30 0001269026 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2020-09-30 0001269026 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2020-09-30 0001269026 us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2020-09-30 0001269026 SINT:CommonStockWarrantsMember 2020-01-01 2020-09-30 0001269026 SINT:CommonStockWarrantsMember 2019-01-01 2019-09-30 0001269026 SINT:CommonStockWarrantsMember 2019-09-30 0001269026 SINT:CommonStockWarrantsMember 2020-09-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2020-09-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2020-09-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2020-09-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2020-09-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-09-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputOptionVolatilityMember srt:MinimumMember 2020-09-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputOptionVolatilityMember srt:MaximumMember 2020-09-30 0001269026 SINT:SeriesCPreferredStockPurchaseWarrantMember 2020-02-29 0001269026 SINT:SeriesCPreferredStockPurchaseWarrantMember 2020-02-01 2020-02-29 0001269026 SINT:WarrantsExercisableMember 2020-02-01 2020-02-29 0001269026 SINT:PreferredSharesMember 2020-02-01 2020-02-29 0001269026 SINT:SeriesCConvertiblePreferredStockMember us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001269026 SINT:FollowingEighteenMonthsPaymentPeriodMember 2020-01-01 2020-09-30 0001269026 SINT:AssetPurchaseAgreementMember 2020-01-01 2020-09-30 0001269026 SINT:ATMEquityDistributionAgreementMember 2019-09-11 2019-09-12 0001269026 2020-07-01 2020-09-30 0001269026 2019-07-01 2019-09-30 0001269026 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001269026 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001269026 us-gaap:CommonStockMember 2019-06-30 0001269026 us-gaap:CommonStockMember 2020-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001269026 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001269026 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001269026 us-gaap:RetainedEarningsMember 2019-06-30 0001269026 us-gaap:RetainedEarningsMember 2020-06-30 0001269026 2020-06-30 0001269026 SINT:PaycheckProtectionProgramMember SINT:PPPLoanMember 2020-04-28 0001269026 SINT:PaycheckProtectionProgramMember SINT:PPPLoanMember 2020-04-27 2020-04-28 0001269026 SINT:TwoRegisteredDirectOfferingsMember 2020-01-01 2020-09-30 0001269026 SINT:SharePurchaseAgreementMember 2020-06-22 2020-06-23 0001269026 SINT:SharePurchaseAgreementMember 2020-06-23 0001269026 SINT:SharePurchaseAgreementMember 2020-06-26 0001269026 SINT:SharePurchaseAgreementMember 2020-06-25 2020-06-26 0001269026 SINT:SharePurchaseAgreementMember 2020-07-16 0001269026 SINT:SharePurchaseAgreementMember 2020-07-15 2020-07-16 0001269026 SINT:FirstPaymentMember 2018-09-29 2018-10-02 0001269026 SINT:SecondPaymentMember 2018-09-29 2018-10-02 0001269026 SINT:SeriesBConvertiblePreferredStockMember us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001269026 SINT:HoldersOfWarrantsOneMember 2020-01-01 2020-09-30 0001269026 SINT:HoldersOfWarrantsOneMember us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001269026 SINT:HoldersOfWarrantsTwoMember 2020-01-01 2020-09-30 0001269026 SINT:HoldersOfWarrantsTwoMember us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001269026 SINT:HoldersOfWarrantsMember 2020-01-01 2020-09-30 0001269026 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001269026 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001269026 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001269026 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001269026 us-gaap:CommonStockMember 2019-03-31 0001269026 us-gaap:CommonStockMember 2020-03-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001269026 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001269026 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001269026 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001269026 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001269026 us-gaap:RetainedEarningsMember 2019-03-31 0001269026 us-gaap:RetainedEarningsMember 2020-03-31 0001269026 2019-01-01 2019-03-31 0001269026 2019-04-01 2019-06-30 0001269026 2020-01-01 2020-03-31 0001269026 2020-04-01 2020-06-30 0001269026 2019-03-31 0001269026 2020-03-31 0001269026 SINT:SharePurchaseAgreementMember 2020-08-04 0001269026 SINT:SharePurchaseAgreementMember 2020-08-03 2020-08-04 0001269026 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001269026 us-gaap:EmployeeStockOptionMember 2020-09-30 0001269026 SINT:TwentyTwentyMember SINT:BoardOfDirectorMember 2020-01-01 2020-09-30 0001269026 SINT:PreferredBStockMember 2019-01-01 2019-03-31 0001269026 SINT:PreferredCStockMember 2019-01-01 2019-03-31 0001269026 SINT:PreferredBStockMember 2019-04-01 2019-06-30 0001269026 SINT:PreferredCStockMember 2019-04-01 2019-06-30 0001269026 SINT:PreferredBStockMember 2019-07-01 2019-09-30 0001269026 SINT:PreferredCStockMember 2019-07-01 2019-09-30 0001269026 SINT:PreferredBStockMember 2020-01-01 2020-03-31 0001269026 SINT:PreferredCStockMember 2020-01-01 2020-03-31 0001269026 SINT:PreferredBStockMember 2020-04-01 2020-06-30 0001269026 SINT:PreferredCStockMember 2020-04-01 2020-06-30 0001269026 SINT:PreferredBStockMember 2020-07-01 2020-09-30 0001269026 SINT:PreferredCStockMember 2020-07-01 2020-09-30 0001269026 SINT:PreferredBStockMember 2018-12-31 0001269026 SINT:PreferredCStockMember 2018-12-31 0001269026 SINT:PreferredBStockMember 2019-03-31 0001269026 SINT:PreferredCStockMember 2019-03-31 0001269026 SINT:PreferredBStockMember 2019-06-30 0001269026 SINT:PreferredCStockMember 2019-06-30 0001269026 SINT:PreferredBStockMember 2019-09-30 0001269026 SINT:PreferredCStockMember 2019-09-30 0001269026 SINT:PreferredBStockMember 2019-12-31 0001269026 SINT:PreferredCStockMember 2019-12-31 0001269026 SINT:PreferredBStockMember 2020-03-31 0001269026 SINT:PreferredCStockMember 2020-03-31 0001269026 SINT:PreferredBStockMember 2020-06-30 0001269026 SINT:PreferredCStockMember 2020-06-30 0001269026 SINT:PreferredBStockMember 2020-09-30 0001269026 SINT:PreferredCStockMember 2020-09-30 0001269026 SINT:TwoRegisteredDirectOfferingMember 2020-01-01 2020-09-30 0001269026 2020-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft Sintx Technologies, Inc. 10-Q 2020-09-30 false --12-31 Non-accelerated Filer

0.01

250000000

2434009

24551059

2434009

24551059

0001269026

0.01

3112000

5100000

3100000

true false

-5296000

-3805000

-2437000

-1446000

-2438000

-1629000

-730000

1169000

-4028000

-1629000

-730000

1169000

-4028000

2020

2500000

1600000

2500000

9400000

2500000

P3Y4M24D

P2Y7M10D

P4Y4M9D

Yes Yes false

9440

6372000

6372350

6337930

75606

165586

3504535

739618

6215742

212168

-9208

-123

-179

-100

-2

3700000

2400000

1500000

3415000

1902520

1200000

1109000

9400000

1100000

1600000 Q3

-2073000

-753000

-144000

533000

461000

106000

72000

639000

535000

50000

9000

13000

41000

37000

220000

1600000

1566000

220000

769000

1600000

-6328000

1750000

754000

1.62

0.00

0.16

0.28

0.00

139.17

160.7

589000

646000

392000 52000

285000

248000

391000

1.50

0.10

0.0425

0.010

2021-10-01

2022-04-28

5006475 739618

675

1000

1.50

1.72

2.00

2.40

1.4814

1200000

6000000

The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable on October 1, 2021

2500000

8500000

6000000

2500000

The amended lease has two five-year extension options.

On June 7, 2019, the lease was amended to extend the rental period through 2024

54428

29732

130000000

249

0.065

-0.10 -0.59 -0.07

1 for 30 reverse stock split

1700000

800000

200000

34000

1600000

138889000

194444000

2500000

-0.07

1600000

500000

The note receivable includes an imputed interest rate of 10%, which totaled $915,725 as of October 31, 2018, and has a 36-month amortization.

The Company leases office, warehouse and manufacturing space under a single operating lease.

Company's option at any time on or after the first anniversary of the expiration of the rights offering or at the option of the holder at any time, into a number of shares of our common stock equal to the quotient of the stated value of the Preferred Stock ($1,000) divided by the Conversion Price ($1.4814 per share).

Each Warrant is exercisable for one share of our common stock at an exercise price of $1.50 per share from the date of issuance through its expiration five years from the date of issuance. The Warrants also contain a cashless exercise provision that allows the holder to receive 70% of the common stock otherwise available under the warrant to the holder electing the cashless exercise provision. 25551059

20015000

1285000

5500000

4100000

3000000

8200000

527896

354500

-2073000 -753000 -144000

1422410

-0.03 -0.59 -0.07

-7369000

-4558000

-2437000

-1590000

-9565000 -2703000 -74000 -345000

-16934000

-7261000

-2511000

-1935000

2000

3197000 44000 0.60

P2Y

915725000

9389

223

1200000

513000

528000

544000

9147000

32633000

-234078000

-239375000

239256000

266665000

24000

246000

3945000

5097000

12000

158000

1867000

1580000

2066000

3359000

23000

25000

6000

238000

360000

393000

220000

1600000

1266000

946000

191000

157000

9147000

32633000

35000

36000

2341000

2031000

1944000

194000

41000

37000

190000

287000

533000

461000

4063000

29587000

1724000

2189000

106000

74000

310000

225000

136000

49000

1787000

27050000

15094276

1269106

22774263

2127293

13671866

1269106

22774263

2127293

-1.12

-5.72

-0.11

-0.91

-0.63 -2.13 -0.16 -0.49 -3.59 -0.11 -0.75

-1.09

-5.13

-0.11

-0.84

-0.70 -2.13 -0.16 -0.39 -3.00 -0.11 -0.68

-14861000

-6508000

-2511000

-1791000

9565000

2703000

74000

345000

-5296000

-3805000

-2437000

-1446000

970000

1148000

-9000

254000

201000

48000

201000

1246000

1750000

754000

-287000

144000

267000

349000

78000

111000

2000

3000

1000

-6266000

-4953000

-2428000

-1700000

6362000

5026000

2441000

1722000

450000

303000

182000

139000

2418000

2166000

827000

714000

3494000

2557000

1432000

869000

96000

73000

13000

22000

382000

364000

53000

151000

478000

437000

66000

173000

2000

2704000 35000 65000 3197000 44000

1787000

27050000

2926000

5447000

25263000

-2521000

30941000

1388000

29000

406000

6328000

103000

1377000

970000

1528000

1111000

151000

141000

-7055000

-4879000

254000

557000

-353000

83000

-104000

35000

73000

-33000

-87000

-154000

-3000

325000

242000

344000

4000

310000 264000

54000

79000

1. Organization and Summary of Significant Accounting Policies   Organization   SINTX Technologies, Inc. (“SINTX” or “the Company”) was incorporated in the state of Delaware on December 10, 1996. SINTX is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride material and components in its FDA registered and ISO 13485:2016 certified facility. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. The Company’s products are primarily sold in the United States.   Reverse Stock Split   On July 26, 2019 the Company effected a 1 for 30 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock shares, equivalents, and per-share amounts for all periods presented in these condensed financial statements have been adjusted retroactively to reflect the reverse stock split.   Basis of Presentation   These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company. In May 2020, the Company dissolved its wholly owned subsidiary ST Sub, Inc. At the time of dissolution the subsidiary had no assets, liabilities, equity, or operations. The financial statements after May 8, 2020, are not consolidated.   SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 26, 2020. The results of operations for the nine months ended September 30, 2020, are not necessarily indicative of the results to be expected for the year ending December 31, 2020. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2019.   Use of Estimates   The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. As of September 30, 2020, the most significant estimates relate to inventory, long-lived and intangible assets, the liability for preferred stock and common stock warrants, and the derivative liabilities.   Liquidity and Capital Resources   The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements.   For the nine months ended September 30, 2020 and 2019, the Company incurred a net loss of $5.3 million and $3.8  million, respectively, and used cash in operations of $7.1 million and $4.9 million, respectively. The Company had an accumulated deficit of $239 million and $234 million  as of September 30, 2020 and December 31, 2019, respectively. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operations or obtain additional financing is uncertain.   The Company is actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of our silicon nitride material are not well known, and we believe the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications.   The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering in February 2014. On February 6, 2020, the Company closed on a rights offering to its stockholders of units, consisting of convertible preferred stock and warrants, for gross proceeds of $9.4 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company of approximately $1.2 million. Additionally, during the period of June 2020 through August 2020, the Company closed four registered direct offerings of shares of its common stock, priced at-the-market under Nasdaq rules, resulting in the issuance of a total of 11,015,000  shares of its common stock for gross proceeds of approximately $20.9  million, before considering issuance costs of approximately $1.6  million (see Note 8).   During the year ended December 31, 2019, the Company entered into an at-the-market (ATM) equity distribution agreement in which the Company may sell, from time to time, shares of common stock having an aggregate offering price of up to $2.5 million. The Company sold 527,896 shares during the year ended December 31, 2019, raising approximately $1.7 million before deducting fees to the placement agent and other offering expenses of approximately $0.2 million. During the nine month period ending September 30, 2020, the Company sold 354,500 shares of common stock, raising approximately $0.8 million deducting fees to the placement agent and other offering expenses of approximately $0.034 million. As of September 30, 2020, no funding capacity is available under the ATM. (see Note 8).   On October 1, 2018, the Company sold the retail spine business to CTL Medical. The sale included a $6 million noninterest bearing note receivable payable over a 36-month term. The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable to occur October 1, 2021. The Company expects cash flows of approximately $2.5  million for the remaining thirteen months.   Management has concluded that together with its existing capital resources and payments on the note receivable from the sale of the Spine business will be sufficient to fund operations for at least the next 12 months, or through November 2021. In the financial statements for the year ended December 31, 2019, the Company concluded substantial doubt existed for the Company to continue as a going concern. Beginning with the period ended March 31, 2020, the Company’s position changed as a result of the capital raises outlined in Note 8.   Risks Related to COVID-19 Pandemic   The recent outbreak of COVID-19 originated in Wuhan, China, in December 2019 and has since spread to multiple countries, including the United States and several European countries. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which we rely.   New Accounting Pronouncements Not Yet Adopted   The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements.

2. Basic and Diluted Net Income (Loss) per Common Share   Basic net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period that are determined to be dilutive. Common stock equivalents are primarily comprised of preferred stock and warrants for the purchase of common stock. For the three months ended September 30, 2020, there is no difference in the number of shares and net loss used to calculate basic and diluted shares outstanding because their effect would have been anti-dilutive. The Company had potentially dilutive securities, totaling approximately 1.6  million and 0.5  million as of September 30, 2020 and 2019, respectively.   Below  are basic and diluted loss per share data for the three months ended September 30, 2020, which are in thousands except for share and per share data:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Basic Calculation</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Effect of Dilutive Warrant Securities</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Diluted Calculation</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Numerator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 53%; padding-left: 10pt">Net loss</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(2,437</td> <td style="width: 1%">)</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(2,437</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(74</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(74</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(2,511</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(2,511</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td> <td> </td> <td> </td> <td style="text-align: right">22,774,263</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">22,774,263</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net loss per common share:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(0.11</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(0.11</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.11</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.11</td> <td>)</td></tr> </table>   Below  are basic and diluted loss per share data for the nine months ended September 30, 2020, which are in thousands except for share and per share data:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Basic Calculation</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Effect of Dilutive Warrant Securities</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Diluted Calculation</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Numerator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 53%; padding-left: 10pt">Net loss</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(5,296</td> <td style="width: 1%">)</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(2,073</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(7,369</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(9,565</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(9,565</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(14,861</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(2,073</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(16,934</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td> <td> </td> <td> </td> <td style="text-align: right">13,671,866</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,422,410</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">15,094,276</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net income (loss) per common share:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(0.39</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.10</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.49</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(0.70</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.07</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(0.63</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net income (loss) attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1.09</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.03</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1.12</td> <td>)</td></tr> </table>   Below  are basic and diluted loss per share data for the three months ended September 30, 2019, which are in thousands except for share and per share data:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Basic Calculation</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Effect of Dilutive Warrant Securities</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Diluted Calculation</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Numerator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 53%; padding-left: 10pt">Net loss</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(1,446</td> <td style="width: 1%">)</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(144</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(1,590</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(345</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(345</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1,791</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(144</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1,935</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td> <td> </td> <td> </td> <td style="text-align: right">2,127,293</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,127,293</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net loss per common share:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(0.68</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.07</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.75</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(0.16</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(0.16</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.84</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.07</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.91</td> <td>)</td></tr> </table>   Below  are basic and diluted loss per share data for the nine months ended September 30, 2019, which are in thousands except for share and per share data:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Basic Calculation</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Effect of Dilutive Warrant Securities</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Diluted Calculation</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Numerator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 53%; padding-left: 10pt">Net loss</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(3,805</td> <td style="width: 1%">)</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(753</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(4,558</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,703</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,703</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(6,508</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(753</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(7,261</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td> <td> </td> <td> </td> <td style="text-align: right">1,269,106</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,269,106</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net loss per common share:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(3.00</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.59</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(3.59</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2.13</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2.13</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(5.13</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.59</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(5.72</td> <td>)</td></tr> </table>

3. Inventories   Inventories consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">461</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">533</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>WIP</td> <td> </td> <td> </td> <td style="text-align: right">72</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">106</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Finished Goods</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">535</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">639</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   As of September 30, 2020, inventories totaling approximately $0.1 million and $0.5 million  were classified as current and long-term, respectively. Inventories classified as current represent the carrying value of inventories as of September 30, 2020, that management estimates will be sold by September 30, 2021.

4. Intangible Assets   Intangible assets consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Trademarks</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">50</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">50</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Less: accumulated amortization</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(13</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(9</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">37</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">41</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Amortization expense for the nine months ended September 30, 2020, was approximately $4.0  thousand. Amortization expense for the nine months ended September 30, 2019, was approximately $4.0  thousand.

5. Fair Value Measurements   Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis   The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 72px">Level 1 -</td> <td style="text-align: justify">quoted market prices for identical assets or liabilities in active markets.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>Level 2 -</td> <td style="text-align: justify">observable prices that are based on inputs not quoted on active markets but corroborated by market data.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>Level 3 -</td> <td style="text-align: justify">unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</td></tr> </table>   The Company classifies assets and liabilities measured at fair value in their entirety based on the lowest level of input that is significant to their fair value measurement. No financial assets were measured on a recurring basis as of September 30, 2020 and December 31, 2019. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of September 30, 2020 and December 31, 2019 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurements as of September  30, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Description</td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative liability</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 42%; padding-left: 10pt">Common stock warrants</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,600</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,600</td> <td style="width: 1%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurements as of December  31, 2019</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Description</td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative liability</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 42%; padding-left: 10pt">Common stock warrants</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">220</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">220</td> <td style="width: 1%"> </td></tr> </table>   The Company did not have any transfers of assets and liabilities between any levels of the fair value measurement hierarchy during the nine months ended September 30, 2020 and 2019 (in thousands).   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Common Stock Warrants</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%">Balance  as of December 31, 2018</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 19%; text-align: right">(1,566</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Change in fair value</td> <td> </td> <td> </td> <td style="text-align: right">754</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercise of warrants</td> <td> </td> <td> </td> <td style="text-align: right">44</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Other, net</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Balance as of September 30, 2019</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(769</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Balance  as of December 31, 2019</td> <td> </td> <td>$</td> <td style="text-align: right">(220</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Issuance of derivatives</td> <td> </td> <td> </td> <td style="text-align: right">(6,328</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Change in fair value</td> <td> </td> <td> </td> <td style="text-align: right">1,750</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercise of warrants</td> <td> </td> <td> </td> <td style="text-align: right">3,197</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Other, net</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Balance as of September 30, 2020</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1,600</td> <td>)</td></tr> </table>   Common Stock Warrants   The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. As of September 30, 2020, and December 31, 2019, the derivative liability was calculated using the Monte Carlo Simulation valuation.   The assumptions used in estimating the common stock warrant liability as of September 30, 2020 and December 31, 2019 were as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 60%">Weighted-average risk-free interest rate</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">0.16%-0.28</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">1.62</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Weighted-average expected life (in years)</td> <td> </td> <td> </td> <td style="text-align: right">2.61-4.36</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.4</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Weighted-average expected volatility </td> <td> </td> <td> </td> <td style="text-align: right">139.17%-160.7</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">64</td> <td>%</td></tr> </table>   Other Financial Instruments   The Company’s recorded values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The recorded value of debt approximates the fair value as the interest rate approximates market interest rates.

6. Accrued Liabilities   Accrued liabilities consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31,2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Payroll and related expense</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">646</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">589</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Resterilization and repackaging costs</td> <td> </td> <td> </td> <td style="text-align: right">52</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">392</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Other</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">248</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">285</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">946</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,266</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

7. Debt   Equipment Loan   In September 2019, the Company entered into a debt arrangement with a finance company to purchase equipment. The debt balance was paid in full during the third quarter 2020.   PPP Loan   On April 28, 2020, the Company received funding under a Paycheck Protection Program (“PPP”) loan (the “PPP Loan”) from First State Community Bank (the “Lender”). The principal amount of the PPP Loan is $0.391  million. The PPP was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (the “SBA”). The PPP Loan has a two-year term, maturing on April 28, 2022. The term may be extended to five-years if the Lender and we agree to do so. The interest rate on the PPP Loan is 1.0% per annum. Principal and interest are payable in 18 monthly installments, beginning on November 28, 2020, until maturity with respect to any portion of the PPP Loan which is not forgiven as described below. The Company did not provide any collateral or guarantees for the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan. The PPP Loan provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects. The Company is permitted to prepay or partially prepay the PPP Loan at any time with no prepayment penalties. The PPP Loan may be partially or fully forgiven if the Company complies with the provisions of the CARES Act, including the use of PPP Loan proceeds for payroll costs, rent, utilities and other expenses, provided that such amounts are incurred during a 24-week period that commenced on April 28, 2020 and at least 60% of any forgiven amount has been used for covered payroll costs as defined by the CARES Act. Any forgiveness of the PPP Loan will be subject to approval by the SBA and the Lender and will require the Company to apply for such treatment in the future.

8. Equity   2020 Rights Offering   During February 2020, the Company closed on a rights offering capital raise wherein the Company’s holders of common stock, Series C Preferred Stock, and certain outstanding warrants on the date of record, obtained, at no charge, non-transferable subscription rights to purchase units (“Units”). Each Unit consisted of one share of Series C Convertible Preferred Stock (“Preferred Stock”) and 675 warrants to purchase common stock (“Warrants”). Each Unit sold for $1,000. Each share of the Preferred Stock is convertible, at the Company’s option at any time on or after the first anniversary of the expiration of the rights offering or at the option of the holder at any time, into a number of shares of our common stock equal to the quotient of the stated value of the Preferred Stock ($1,000) divided by the Conversion Price ($1.4814 per share). Each Warrant is exercisable for one share of our common stock at an exercise price of $1.50 per share from the date of issuance through its expiration five years from the date of issuance. The Warrants also contain a cashless exercise provision that allows the holder to receive 70% of the common stock otherwise available under the warrant to the holder electing the cashless exercise provision. The Company issued 9,440 Units, which includes 6,372,000 Warrants exercisable into shares of our common stock and preferred shares that are convertible into 6,372,350 shares of Common Stock, for gross proceeds of $9.4 million.   The Company raised $9.4 million, before consideration of issuance costs, associated with the issuance of the Units, with $3.1 million allocated to the preferred stock (with no issuance costs allocated to the preferred stock) and $5.1 million, net of issuance costs of approximately $1.2 million, allocated to the warrants. In association with the warrants that were recorded as a derivative liability, the Company immediately expensed approximately all $1.2 million of the issuance costs.   During the nine months ended September 30, 2020, Series B Convertible Preferred stockholders of the Company converted 223 shares of Series B Convertible Preferred Stock into 165,586 shares of common stock, and Series C Convertible Preferred stockholders of the Company converted 9,389 shares of Series C Convertible Preferred Stock into 6,337,930 shares of common stock.   Also, during the nine months ended September 30, 2020, holders of Warrants electing to use the cashless exercise option exercised 5,006,475 warrants, which resulted in the issuance of 3,504,535 shares of common stock. During the same period of time, holders of Warrants electing to exercise warrants for cash exercised 739,618 warrants, which resulted in the issuance of 739,618 shares of common stock, and the receipt of $1.1 million of cash.   2020 Registered Direct Offerings   During June 2020, the Company closed two registered direct offerings of shares of its common stock, priced at-the-market under Nasdaq rules, resulting in the issuance of a total of 6,100,000 shares of its common stock for gross proceeds of approximately $9.6 million, before considering issuance costs of approximately $0.8 million. On June 23, 2020, the Company entered into a Share Purchase Agreement with certain institutional purchasers, pursuant to which the Company agreed to issue and sell to the purchasers, in a registered direct offering, an aggregate of 3,700,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $1.50 per share for aggregate gross proceeds to the Company of approximately $5.5 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company. Following the initial registered direct offering, on June 26, 2020, the Company entered into another Share Purchase Agreement with certain institutional purchasers pursuant to which the Company offered to the purchasers, in a registered direct offering, an aggregate of 2,400,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $1.72 per share for aggregate gross proceeds to the Company of approximately $4.1 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company.   On July 16, 2020, the Company entered into a Share Purchase Agreement with certain institutional purchasers, pursuant to which the Company agreed to issue and sell to the purchasers, in a registered direct offering, an aggregate of 1,500,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $2.00 per share for aggregate gross proceeds to the Company of $3.0 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company.   On August 4, 2020, the Company entered into a Share Purchase Agreement with certain institutional purchasers, pursuant to which the Company agreed to issue and sell to the purchasers, in a registered direct offering, an aggregate of 3,415,000 shares of common stock, par value $0.01 per share. The shares were sold at a negotiated purchase price of $2.40 per share for aggregate gross proceeds to the Company of $8.2 million, before deducting fees to the placement agent and other estimated offering expenses payable by the Company.   2019 ATM Stock Offerings    On June 4, 2019, the Company entered into an Equity Distribution Agreement, (the “Distribution Agreement”), with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell from time to time, shares of its common stock, having an aggregate offering price of up to $1.6 million through Maxim, as agent (the “ATM Offering”). On September 12, 2019, the Company entered into an amendment to the Distribution Agreement with Maxim, which increased the maximum aggregate offering price of the shares of the Company’s common stock from $1.6 million to $2.5 million. Subject to the terms and conditions of the Distribution Agreement, Maxim will use its commercially reasonable efforts to sell the shares from time to time, based on the Company’s instructions. The Company has no obligation to sell any of the shares and may at any time suspend offers under the Distribution Agreement. The Offering will terminate upon the earlier of (i) the sale of Shares having an aggregate offering price of $2.5 million, (ii) the termination of the Distribution Agreement by either Maxim or the Company upon the provision of fifteen (15) days written notice, or (iii) September 12, 2020. The Company agrees to pay Maxim a transaction fee at a fixed rate of 4.25% of the gross sales price of shares sold under the Distribution Agreement and agreed to provide indemnification and contribution to Maxim with respect to certain liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. During the year ended December 31, 2019, the Company raised approximately $1.7 million before deducting fees to the placement agent and other offering expenses of approximately $0.2 million, through the issuance of 527,896 shares of common stock under the Distribution Agreement with Maxim. During the nine month period ending September 30, 2020, the Company sold 354,500 shares of common stock, raising approximately $0.8 million before deducting issuance fees of approximately $0.034 million. As of September 30, 2020, no funding capacity is available under the ATM.

9. Stock-Based Compensation   During the three months ended September 30, 2020 the shareholders approved the 2020 Equity Incentive Plan. The 2020 Plan provides for the grant of nonqualified stock options, incentive stock options, restricted stock, restricted stock units, stock appreciation rights (SARs), and performance share awards to employees, officers, consultants, advisors, non-employee directors and independent contractors designated by either the board of directors of the Company or if so authorized by the board of directors, the Compensation Committee (the “Committee”) of the Board of Directors. Under the 2020 Plan, the maximum number of shares of common stock which may be issued, subject to adjustment as described below, is 1,902,520 shares of common stock, which includes 2,520 shares that have been rolled over from our 2012 Plan, as amended.   A summary  of the Company’s outstanding stock option activity for the nine months ended September 30, 2020 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Options</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted- Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted- Average Remaining Contractual Life (Years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Intrinsic Value</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 46%">As of December 31, 2019</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">377</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">7,446.69</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">5.3</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Granted</td> <td> </td> <td> </td> <td style="text-align: right">515,017</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.47</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10.0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Expired</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>As of September 30, 2020</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">515,394</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">5.90</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9.6</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">746,774</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercisable as of September 30, 2020</td> <td> </td> <td> </td> <td style="text-align: right">377</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">7,446.69</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.6</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td></tr> </table>   The Company estimates the fair value of each stock option on the grant date using the Black-Scholes-Merton valuation model, which requires several estimates including an estimate of the fair value of the underlying common stock on grant date. The expected volatility was based on an average of the historical volatility the Company. The expected term was calculated utilizing the simplified method. The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the option. The following weighted average assumptions were used in the calculation to estimate the fair value of options granted to employees during the nine months ended September 30, 2020.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2" style="text-align: center">Nine Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; text-align: justify">Weighted-average risk-free interest rate</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 17%; text-align: right">0.34</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Weighted-average expected life (in years)</td> <td> </td> <td> </td> <td style="text-align: right">10.0</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Weighted-average expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">129.69</td> <td>%</td></tr> </table>   Unrecognized stock-based compensation as of September 30, 2020 is as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Unrecognized Stock-Based</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining of Recognition</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Compensation</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">(in years)</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; text-align: justify">Stock options</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">204</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">2.6</td> <td style="width: 1%"> </td></tr> </table>

10. Commitments and Contingencies   The Company has executed agreements with certain executive officers of the Company which, upon the occurrence of certain events related to a change in control, call for payments to the executives up to three times their annual salary and accelerated vesting of previously granted stock options.   From time to time, the Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. Management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s financial position, operating results or cash flows.

11. Note Receivable   On October 1, 2018, the Company completed the sale of its retail spine business to CTL Medical. The sale included a $6 million noninterest bearing note receivable. The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable on October 1, 2021. The note receivable includes an imputed interest rate of 10%, which totaled $915,725 as of October 31, 2018, and has a 36-month amortization. As of September 30, 2020, the net carrying value of the note receivable was approximately $2.4  million, with expected cash proceeds of $2.5 million.

12. Discontinued Operations   The Company and CTL Medical entered in an asset purchase agreement on October 1, 2018, whereby CTL Medical agreed to acquire all of the Company’s commercial spine business for total consideration of $8.5 million, which includes a $6.0 million (including interest) note receivable and CTL Medical’s assumption of the Company’s $2.5 million related party note payable to North Stadium. As a result of the closing, CTL Medical is now the exclusive owner of SINTX’s portfolio of metal and silicon nitride spine products, which are presently sold under the brand names of Taurus, Preference, and Valeo, with access to future silicon nitride spine technologies. The Company has agreed to pay the cost, if any, to re-sterilize and re-package select silicon nitride spinal inventories sold to CTL Medical if the sterilization date expires prior to CTL Medical selling the inventories to a third-party customer. This agreement extends for a total of 24 months, ending on September 30, 2020. The Company estimates the sterilization and repackaging cost to approximate $0.1  million at September 30, 2020. Manufacturing, R&D, and all intellectual property related to the core, non-spine, biomaterial technology of silicon nitride remains with the Company in Salt Lake City. The Company will serve as CTL’s exclusive OEM provider of silicon nitride products.

13. Leases   The Company leases office, warehouse and manufacturing space under a single operating lease. On June 7, 2019, the lease was amended to extend the rental period through 2024 and reduce the amount of space leased from 54,428 square feet to 29,732 square feet. The new rent was effective January 1, 2020. The amended lease has two five-year extension options. As of September 30, 2020, the operating lease right-of-use asset totaled approximately $2.0 million and the operating lease liability totaled approximately $2.0 million. Non-cash operating lease expense during the nine months ended September 30, 2020, totaled approximately $0.3  million. As of September 30, 2020, the weighted-average discount rate for the Company’s operating lease was 6.5%.   Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. The Company accounts for lease components separately from the non-lease components. The depreciable life of the assets and leasehold improvements are limited by the expected lease term.   Operating lease future minimum payments together with the present values as of September 30, 2020, are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify">Years Ending December 31,</td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September  30, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 85%">2020</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">124</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2021</td> <td> </td> <td> </td> <td style="text-align: right">513</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2022</td> <td> </td> <td> </td> <td style="text-align: right">528</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2023</td> <td> </td> <td> </td> <td style="text-align: right">544</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2024</td> <td> </td> <td> </td> <td style="text-align: right">561</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Thereafter</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Total future minimum lease payments</td> <td> </td> <td> </td> <td style="text-align: right">2,270</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Less amounts representing interests</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(297</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Present value of lease liability</td> <td> </td> <td> </td> <td style="text-align: right">1,973</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Current-portion of operating lease liability</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">393</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Long-term portion operating lease liability</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,580</td> <td> </td></tr> </table>

Organization   SINTX Technologies, Inc. (“SINTX” or “the Company”) was incorporated in the state of Delaware on December 10, 1996. SINTX is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride material and components in its FDA registered and ISO 13485:2016 certified facility. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. The Company’s products are primarily sold in the United States. Reverse Stock Split   On July 26, 2019 the Company effected a 1 for 30 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock shares, equivalents, and per-share amounts for all periods presented in these condensed financial statements have been adjusted retroactively to reflect the reverse stock split.

Basis of Presentation   These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company. In May 2020, the Company dissolved its wholly owned subsidiary ST Sub, Inc. At the time of dissolution the subsidiary had no assets, liabilities, equity, or operations. The financial statements after May 8, 2020, are not consolidated.   SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 26, 2020. The results of operations for the nine months ended September 30, 2020, are not necessarily indicative of the results to be expected for the year ending December 31, 2020. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2019.

Use of Estimates   The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. As of September 30, 2020, the most significant estimates relate to inventory, long-lived and intangible assets, the liability for preferred stock and common stock warrants, and the derivative liabilities.

Liquidity and Capital Resources   The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements.   For the nine months ended September 30, 2020 and 2019, the Company incurred a net loss of $5.3 million and $3.8  million, respectively, and used cash in operations of $7.1 million and $4.9 million, respectively. The Company had an accumulated deficit of $239 million and $234 million  as of September 30, 2020 and December 31, 2019, respectively. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operations or obtain additional financing is uncertain.   The Company is actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of our silicon nitride material are not well known, and we believe the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications.   The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering in February 2014. On February 6, 2020, the Company closed on a rights offering to its stockholders of units, consisting of convertible preferred stock and warrants, for gross proceeds of $9.4 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company of approximately $1.2 million. Additionally, during the period of June 2020 through August 2020, the Company closed four registered direct offerings of shares of its common stock, priced at-the-market under Nasdaq rules, resulting in the issuance of a total of 11,015,000  shares of its common stock for gross proceeds of approximately $20.9  million, before considering issuance costs of approximately $1.6  million (see Note 8).   During the year ended December 31, 2019, the Company entered into an at-the-market (ATM) equity distribution agreement in which the Company may sell, from time to time, shares of common stock having an aggregate offering price of up to $2.5 million. The Company sold 527,896 shares during the year ended December 31, 2019, raising approximately $1.7 million before deducting fees to the placement agent and other offering expenses of approximately $0.2 million. During the nine month period ending September 30, 2020, the Company sold 354,500 shares of common stock, raising approximately $0.8 million deducting fees to the placement agent and other offering expenses of approximately $0.034 million. As of September 30, 2020, no funding capacity is available under the ATM. (see Note 8).   On October 1, 2018, the Company sold the retail spine business to CTL Medical. The sale included a $6 million noninterest bearing note receivable payable over a 36-month term. The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable to occur October 1, 2021. The Company expects cash flows of approximately $2.5  million for the remaining thirteen months.   Management has concluded that together with its existing capital resources and payments on the note receivable from the sale of the Spine business will be sufficient to fund operations for at least the next 12 months, or through November 2021. In the financial statements for the year ended December 31, 2019, the Company concluded substantial doubt existed for the Company to continue as a going concern. Beginning with the period ended March 31, 2020, the Company’s position changed as a result of the capital raises outlined in Note 8. Risks Related to COVID-19 Pandemic   The recent outbreak of COVID-19 originated in Wuhan, China, in December 2019 and has since spread to multiple countries, including the United States and several European countries. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which we rely.

New Accounting Pronouncements Not Yet Adopted   The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements.

Below  are basic and diluted loss per share data for the three months ended September 30, 2020, which are in thousands except for share and per share data:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Basic Calculation</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Effect of Dilutive Warrant Securities</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Diluted Calculation</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Numerator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 53%; padding-left: 10pt">Net loss</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(2,437</td> <td style="width: 1%">)</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(2,437</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(74</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(74</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(2,511</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(2,511</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td> <td> </td> <td> </td> <td style="text-align: right">22,774,263</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">22,774,263</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net loss per common share:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(0.11</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">(0.11</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.11</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.11</td> <td>)</td></tr> </table>   Below  are basic and diluted loss per share data for the nine months ended September 30, 2020, which are in thousands except for share and per share data:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Basic Calculation</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Effect of Dilutive Warrant Securities</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Diluted Calculation</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Numerator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 53%; padding-left: 10pt">Net loss</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(5,296</td> <td style="width: 1%">)</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(2,073</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(7,369</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(9,565</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(9,565</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(14,861</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(2,073</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(16,934</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td> <td> </td> <td> </td> <td style="text-align: right">13,671,866</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,422,410</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">15,094,276</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net income (loss) per common share:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(0.39</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.10</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.49</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(0.70</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.07</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(0.63</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net income (loss) attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1.09</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.03</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1.12</td> <td>)</td></tr> </table>   Below  are basic and diluted loss per share data for the three months ended September 30, 2019, which are in thousands except for share and per share data:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Basic Calculation</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Effect of Dilutive Warrant Securities</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Diluted Calculation</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Numerator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 53%; padding-left: 10pt">Net loss</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(1,446</td> <td style="width: 1%">)</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(144</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(1,590</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(345</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(345</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1,791</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(144</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1,935</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td> <td> </td> <td> </td> <td style="text-align: right">2,127,293</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,127,293</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net loss per common share:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(0.68</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.07</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.75</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(0.16</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(0.16</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.84</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.07</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.91</td> <td>)</td></tr> </table>   Below  are basic and diluted loss per share data for the nine months ended September 30, 2019, which are in thousands except for share and per share data:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Basic Calculation</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Effect of Dilutive Warrant Securities</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Diluted Calculation</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Numerator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 53%; padding-left: 10pt">Net loss</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(3,805</td> <td style="width: 1%">)</td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(753</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">(4,558</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,703</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,703</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(6,508</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(753</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(7,261</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Denominator:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td> <td> </td> <td> </td> <td style="text-align: right">1,269,106</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,269,106</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Net loss per common share:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(3.00</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(0.59</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">(3.59</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Deemed dividend and accretion of a discount</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2.13</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2.13</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Net loss attributable to common stockholders</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(5.13</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(0.59</td> <td>)</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(5.72</td> <td>)</td></tr> </table>

Inventories consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Raw materials</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">461</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">533</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>WIP</td> <td> </td> <td> </td> <td style="text-align: right">72</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">106</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Finished Goods</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">535</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">639</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Intangible assets consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Trademarks</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">50</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">50</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Less: accumulated amortization</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(13</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(9</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">37</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">41</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of September 30, 2020 and December 31, 2019 (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurements as of September  30, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Description</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative liability</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 44%; padding-left: 10pt">Common stock warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,600</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,600</td> <td style="width: 1%"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurements as of December  31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Description</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative liability</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 44%; padding-left: 10pt">Common stock warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">220</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">220</td> <td style="width: 1%"> </td></tr> </table>

The Company did not have any transfers of assets and liabilities between any levels of the fair value measurement hierarchy during the nine months ended September 30, 2020 and 2019 (in thousands).   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Common Stock Warrants</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%">Balance  as of December 31, 2018</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">(1,566</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Change in fair value</td> <td> </td> <td> </td> <td style="text-align: right">754</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercise of warrants</td> <td> </td> <td> </td> <td style="text-align: right">44</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Other, net</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Balance as of September 30, 2019</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(769</td> <td style="padding-bottom: 2.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Balance  as of December 31, 2019</td> <td> </td> <td>$</td> <td style="text-align: right">(220</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Issuance of derivatives</td> <td> </td> <td> </td> <td style="text-align: right">(6,328</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Change in fair value</td> <td> </td> <td> </td> <td style="text-align: right">1,750</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercise of warrants</td> <td> </td> <td> </td> <td style="text-align: right">3,197</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Other, net</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Balance as of September 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(1,600</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>

The assumptions used in estimating the common stock warrant liability as of September 30, 2020 and December 31, 2019 were as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 60%">Weighted-average risk-free interest rate</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">0.16%-0.28</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">1.62</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Weighted-average expected life (in years)</td> <td> </td> <td> </td> <td style="text-align: right">2.61-4.36</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.4</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Weighted-average expected volatility </td> <td> </td> <td> </td> <td style="text-align: right">139.17%-160.7</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">64</td> <td>%</td></tr> </table>

Accrued liabilities consisted of the following (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31,2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Payroll and related expense</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">646</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">589</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Resterilization and repackaging costs</td> <td> </td> <td> </td> <td style="text-align: right">52</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">392</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Other</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">248</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">285</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">946</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,266</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A summary  of the Company’s outstanding stock option activity for the nine months ended September 30, 2020 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted- Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted- Average Remaining Contractual Life (Years)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Intrinsic Value</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">As of December 31, 2019</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">377</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">7,446.69</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">5.3</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Granted</td> <td> </td> <td> </td> <td style="text-align: right">515,017</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.47</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10.0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">As of September 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">515,394</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">5.90</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9.6</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">746,774</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercisable as of September 30, 2020</td> <td> </td> <td> </td> <td style="text-align: right">377</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">7,446.69</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.6</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td></tr> </table>

Unrecognized stock-based compensation as of September 30, 2020 is as follows (in thousands):   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Unrecognized Stock-Based</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining of Recognition</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Compensation</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">(in years)</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%; text-align: justify">Stock options</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">204</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">2.6</td> <td style="width: 1%"> </td></tr> </table>

Operating lease future minimum payments together with the present values as of September 30, 2020, are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify">Years Ending December 31,</td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September  30, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 85%">2020</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">124</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2021</td> <td> </td> <td> </td> <td style="text-align: right">513</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2022</td> <td> </td> <td> </td> <td style="text-align: right">528</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2023</td> <td> </td> <td> </td> <td style="text-align: right">544</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2024</td> <td> </td> <td> </td> <td style="text-align: right">561</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Thereafter</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Total future minimum lease payments</td> <td> </td> <td> </td> <td style="text-align: right">2,270</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Less amounts representing interests</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(297</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Present value of lease liability</td> <td> </td> <td> </td> <td style="text-align: right">1,973</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Current-portion of operating lease liability</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">393</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Long-term portion operating lease liability</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,580</td> <td> </td></tr> </table>

11015000 6100000

20900000

9600000

1000

-1000

100000

300000

124000

561000

2270000

297000

1973000

515017

0.47

377

515394

377

7446.69

5.90

7446.69

P5Y3M19D P10Y0M0D

P9Y7M6D

P4Y7M6D

746774000

P2Y7M6D

2520

204000

5202000

27536000

7000

237673000

-229281000

24000

239256000

-234078000

6028000

246000

24000

266665000

239090000

-239375000

-233086000

8399

6440000

18000

194000

238062000

255939000

-231640000

-236937000

19196000

7000

118000

237673000

243999000

-230910000

-232909000

6770000

11208000

726455

2434009

24551059

2363991

1854898

19430913

726455

11778746

4074

737

249

232

126

101000 101000 2000 2000 35374 500 160256 983528 -3337 -488 2000 -2000 10000 -10000

29000

1000

10368000 890000 4000 50000 886000 10318000 1000 65000 395000 9583000 396000 9648000 313463 4915000 144415 6454381 43000 43000 1000 1000 190000 190000 1557000 1451000 1557000 1451000 191000 1000 190000 6000 911000 917000 127650 100 611868 3112000 3112000 9440

1000

-1000

62000

2000

-62000

-2000

168000

3111000

-3111000

74000 74000 6173000 207000 6173000 207000

-74000

-6173000

-207000

-6173000

-207000

32000 3000 -32000 -3000 1890 3128895 373750

29000

2000

1.2969

0.0034 P10Y The following weighted average assumptions were used in the calculation to estimate the fair value of options granted to employees during the nine months ended September 30, 2020.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="2" style="text-align: center">Nine Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2020</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; text-align: justify">Weighted-average risk-free interest rate</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 17%; text-align: right">0.34</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Weighted-average expected life (in years)</td> <td> </td> <td> </td> <td style="text-align: right">10.0</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">Weighted-average expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">129.69</td> <td>%</td></tr> </table> 0.000

EX-101.SCH 6 sint-20200930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Note Receivable link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Basic and Diluted Net Income (Loss) per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share - Schedule of Basic and Diluted Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Inventories (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Inventories - Schedule of Components of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurement Hierarchy of Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Fair Value Measurements - Schedule of Assumptions Used in Estimating Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Stock-Based Compensation - Schedule of Assumption Used for Fair value of Option (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Stock-Based Compensation - Schedule of Unrecognized Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Note Receivable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Discontinued Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Leases - Schedule of Operating Lease Future Minimum Payments (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 sint-20200930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 sint-20200930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 sint-20200930_lab.xml XBRL LABEL FILE Indefinite Lived Intangible Assets By Major Class [Axis] Trademarks [Member] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 1 [Member] Measurement Frequency [Axis] Fair Value, Measurements, Recurring [Member] Equity Components [Axis] Common Stock Warrants [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Common Stock [Member] Paid-In Capital [Member] Accumulated Deficit [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Asset Purchase Agreement [Member] Receivable Type [Axis] Interest Note Receivable [Member] Short-term Debt, Type [Axis] Related Party Note Payable [Member] Liability Class [Axis] Valuation Approach and Technique [Axis] Black-Scholes-Merton Valuation Model [Member] Measurement Input Type [Axis] Weighted-Average Risk-Free Interest Rate [Member] Expected Dividend Yield [Member] Weighted Average Expected Volatility [Member] Class of Stock [Axis] Series B Convertible Preferred Stock [Member] ATM Equity Distribution Agreement [Member] Range [Axis] Maximum [Member] Weighted-Average Expected Life (in years) [Member] Minimum [Member] Series C Convertible Preferred Stock [Member] Series C Preferred Stock Purchase Warrant [Member] Warrants Exercisable [Member] Preferred Shares [Member] Scenario [Axis] Following 18-Month Payment Period [Member] PPP Loan [Member] Debt Instrument [Axis] PPP Loan [Member] Two Registered Direct Offerings [Member] Share Purchase Agreement [Member] Award Date [Axis] First Payment [Member] Second Payment [Member] Title of Individual [Axis] Holders of Warrants One [Member] Holders of Warrants Two [Member] Holders of Warrants [Member] Related Party [Axis] Employee Stock Option [Member] Sale of Stock [Axis] Plan Name [Axis] 2020 [Member] Board of Directors [Member] Preferred B Stock [Member] Preferred C Stock [Member] Two Registered Direct Offerings [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] Assets Current assets: Cash and cash equivalents Account and other receivables Prepaid expenses and other current assets Inventories, net Notes receivable, current portion Total current assets Inventories, net Property and equipment, net Intangible assets, net Long-term note receivable, net of current portion Operating lease right-of-use-asset Other long-term assets Total assets Liabilities and Stockholders' Equity Current liabilities: Accounts payable Accrued liabilities Derivative liabilities Current portion of operating lease liability Current portion of debt Other current liabilities Total current liabilities Operating lease liability, net of current portion Long term debt Total liabilities Commitments and contingencies Stockholders' Equity: Convertible preferred stock, value Common stock, $0.01 par value, 250,000,000 shares authorized; 24,551,059 shares, and 2,434,009 shares issued and outstanding at September 30, 2020 and December 31, 2019. Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Convertible preferred stock, par value Convertible preferred stock, shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Product revenue Costs of revenue Gross profit Operating expenses: Research and development General and administrative Sales and marketing Total operating expenses Loss from operations Other income (expenses): Interest expense Interest income Change in fair value of derivative liabilities Offering costs Other income, net Total other income (expense), net Net loss before income taxes Provision for income taxes Net loss Deemed dividend related to the beneficial conversion feature and accretion of a discount on series B preferred stock Net loss attributable to common stockholders Net loss per share - basic and diluted Basic - net loss Basic - deemed dividend and accretion of a discount on conversion of preferred stock Basic - attributable to common stockholders Diluted - net loss Diluted - deemed dividend and accretion of a discount on conversion of preferred stock Diluted - attributable to common stockholders Weighted average common shares outstanding: Basic Diluted Balance Balance, shares Common stock issued from exercise of warrants for cash Common stock issued from exercise of warrants for cash, shares Common stock issued due to conversion of preferred stock Common stock issued due to conversion of preferred stock, shares Stock based compensation Common stock issued for cash, net of fees Common stock issued for cash, net of fees, shares Removal of derivative liability upon exercise of warrant Extinguishment of derivative liability upon exercise of warrant Extinguishment of derivative liability upon exercise of warrant, shares Issuance of common stock from the exercise of warrants for cash Issuance of common stock from the exercise of warrants for cash, shares Issuance of common stock from the cashless exercise of warrants Issuance of common stock from the cashless exercise of warrants, shares Preferred stock issued for cash, net of fees Preferred stock issued for cash, net of fees, shares Common stock issued on conversion of preferred stock Common stock issued on conversion of preferred stock, shares Issuance of agent warrants Beneficial conversion feature on issuance of convertible preferred stock Deemed dividend related to the issuance of preferred stock Accretion of convertible preferred stock discount Deemed dividend related to the conversion of preferred stock Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Cash Flow From Operating Activities Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Amortization of right of use asset Amortization of intangible assets Non-cash interest income Stock based compensation Change in fair value of derivative liabilities Offering Costs Bad debt expense Changes in operating assets and liabilities: Trade accounts receivable EX-101.PRE 10 sint-20200930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2020	Nov. 10, 2020
Cover [Abstract]
Entity Registrant Name	Sintx Technologies, Inc.
Entity Central Index Key	0001269026
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		25,551,059
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 27,050,000	$ 1,787,000
Account and other receivables	49,000	136,000
Prepaid expenses and other current assets	225,000	310,000
Inventories, net	74,000	106,000
Notes receivable, current portion	2,189,000	1,724,000
Total current assets	29,587,000	4,063,000
Inventories, net	461,000	533,000
Property and equipment, net	287,000	190,000
Intangible assets, net	37,000	41,000
Long-term note receivable, net of current portion	194,000	1,944,000
Operating lease right-of-use-asset	2,031,000	2,341,000
Other long-term assets	36,000	35,000
Total assets	32,633,000	9,147,000
Current liabilities:
Accounts payable	157,000	191,000
Accrued liabilities	946,000	1,266,000
Derivative liabilities	1,600,000	220,000
Current portion of operating lease liability	393,000	360,000
Current portion of debt	238,000	6,000
Other current liabilities	25,000	23,000
Total current liabilities	3,359,000	2,066,000
Operating lease liability, net of current portion	1,580,000	1,867,000
Long term debt	158,000	12,000
Total liabilities	5,097,000	3,945,000
Stockholders' Equity:
Common stock, $0.01 par value, 250,000,000 shares authorized; 24,551,059 shares, and 2,434,009 shares issued and outstanding at September 30, 2020 and December 31, 2019.	246,000	24,000
Additional paid-in capital	266,665,000	239,256,000
Accumulated deficit	(239,375,000)	(234,078,000)
Total stockholders' equity	27,536,000	5,202,000
Total liabilities and stockholders' equity	32,633,000	9,147,000
Series B Convertible Preferred Stock [Member]
Stockholders' Equity:
Convertible preferred stock, value
Series C Convertible Preferred Stock [Member]
Stockholders' Equity:
Convertible preferred stock, value

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	24,551,059	2,434,009
Common stock, shares outstanding	24,551,059	2,434,009
Series B Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	130,000,000	130,000,000
Convertible preferred stock, shares issued	26	249
Convertible preferred stock, shares outstanding	26	249
Series C Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	130,000,000	130,000,000
Convertible preferred stock, shares issued	51	0
Convertible preferred stock, shares outstanding	51	0

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Product revenue	$ 66	$ 173	$ 478	$ 437
Costs of revenue	53	151	382	364
Gross profit	13	22	96	73
Operating expenses:
Research and development	1,432	869	3,494	2,557
General and administrative	827	714	2,418	2,166
Sales and marketing	182	139	450	303
Total operating expenses	2,441	1,722	6,362	5,026
Loss from operations	(2,428)	(1,700)	(6,266)	(4,953)
Other income (expenses):
Interest expense	(1)	(1)	(2)	(3)
Interest income	78	111	267	349
Change in fair value of derivative liabilities	(287)	144	1,750	754
Offering costs			(1,246)
Other income, net	201		201	48
Total other income (expense), net	(9)	254	970	1,148
Net loss before income taxes	(2,437)	(1,446)	(5,296)	(3,805)
Provision for income taxes
Net loss	(2,437)	(1,446)	(5,296)	(3,805)
Deemed dividend related to the beneficial conversion feature and accretion of a discount on series B preferred stock	(74)	(345)	(9,565)	(2,703)
Net loss attributable to common stockholders	$ (2,511)	$ (1,791)	$ (14,861)	$ (6,508)
Net loss per share - basic and diluted
Basic - net loss	$ (0.11)	$ (0.68)	$ (0.39)	$ (3.00)
Basic - deemed dividend and accretion of a discount on conversion of preferred stock		(0.16)	(0.70)	(2.13)
Basic - attributable to common stockholders	(0.11)	(0.84)	(1.09)	(5.13)
Diluted - net loss	(0.11)	(0.75)	(0.49)	(3.59)
Diluted - deemed dividend and accretion of a discount on conversion of preferred stock		(0.16)	(0.63)	(2.13)
Diluted - attributable to common stockholders	$ (0.11)	$ (0.91)	$ (1.12)	$ (5.72)
Weighted average common shares outstanding:
Basic	22,774,263	2,127,293	13,671,866	1,269,106
Diluted	22,774,263	2,127,293	15,094,276	1,269,106

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred B Stock [Member]	Preferred C Stock [Member]	Common Stock [Member]	Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018			$ 7,000	$ 237,673,000	$ (229,281,000)	$ 8,399
Balance, shares at Dec. 31, 2018	4,074		726,455
Net loss					(1,629,000)	(1,629,000)
Balance at Mar. 31, 2019			$ 7,000	237,673,000	(230,910,000)	6,770,000
Balance, shares at Mar. 31, 2019	4,074		726,455
Balance at Dec. 31, 2018			$ 7,000	237,673,000	(229,281,000)	8,399
Balance, shares at Dec. 31, 2018	4,074		726,455
Net loss						(3,805,000)
Balance at Sep. 30, 2019			$ 24,000	239,090,000	(233,086,000)	6,028,000
Balance, shares at Sep. 30, 2019	249		2,363,991
Balance at Mar. 31, 2019			$ 7,000	237,673,000	(230,910,000)	6,770,000
Balance, shares at Mar. 31, 2019	4,074		726,455
Common stock issued from exercise of warrants for cash				$ 2,000		$ 2,000
Common stock issued from exercise of warrants for cash, shares			500
Common stock issued due to conversion of preferred stock			$ 10,000	$ (10,000)
Common stock issued due to conversion of preferred stock, shares	(3,337)		983,528
Stock based compensation				1,000		1,000
Common stock issued for cash, net of fees			$ 1,000	$ 395,000		$ 396,000
Common stock issued for cash, net of fees, shares			144,415
Removal of derivative liability upon exercise of warrant				$ 1,000		$ 1,000
Net loss					(730,000)	(730,000)
Balance at Jun. 30, 2019			$ 18,000	238,062,000	(231,640,000)	6,440,000
Balance, shares at Jun. 30, 2019	737		1,854,898
Common stock issued from exercise of warrants for cash				$ 101,000		$ 101,000
Common stock issued from exercise of warrants for cash, shares			35,374
Common stock issued due to conversion of preferred stock			$ 2,000	$ (2,000)
Common stock issued due to conversion of preferred stock, shares	(488)		160,256
Stock based compensation
Common stock issued for cash, net of fees			$ 4,000	886,000		890,000
Common stock issued for cash, net of fees, shares			313,463
Removal of derivative liability upon exercise of warrant				43,000		43,000
Net loss					(1,446,000)	(1,446,000)
Balance at Sep. 30, 2019			$ 24,000	239,090,000	(233,086,000)	6,028,000
Balance, shares at Sep. 30, 2019	249		2,363,991
Balance at Dec. 31, 2019			$ 24,000	239,256,000	(234,078,000)	5,202,000
Balance, shares at Dec. 31, 2019	249		2,434,009
Extinguishment of derivative liability upon exercise of warrant				$ 1,557,000		$ 1,557,000
Extinguishment of derivative liability upon exercise of warrant, shares
Issuance of common stock from the exercise of warrants for cash
Issuance of common stock from the exercise of warrants for cash, shares			100
Issuance of common stock from the cashless exercise of warrants			$ 32,000	$ (32,000)
Issuance of common stock from the cashless exercise of warrants, shares			3,128,895
Preferred stock issued for cash, net of fees				$ 3,112,000		$ 3,112,000
Preferred stock issued for cash, net of fees, shares		9,440
Common stock issued on conversion of preferred stock			$ 62,000	$ (62,000)
Common stock issued on conversion of preferred stock, shares		(9,208)	6,215,742
Issuance of agent warrants				$ 168,000		$ 168,000
Beneficial conversion feature on issuance of convertible preferred stock				3,111,000		3,111,000
Deemed dividend related to the issuance of preferred stock				(3,111,000)		(3,111,000)
Accretion of convertible preferred stock discount				6,173,000		6,173,000
Deemed dividend related to the conversion of preferred stock				(6,173,000)		(6,173,000)
Net loss					1,169,000	1,169,000
Balance at Mar. 31, 2020			$ 118,000	243,999,000	(232,909,000)	11,208,000
Balance, shares at Mar. 31, 2020	249	232	11,778,746
Balance at Dec. 31, 2019			$ 24,000	239,256,000	(234,078,000)	5,202,000
Balance, shares at Dec. 31, 2019	249		2,434,009
Net loss						(5,296,000)
Balance at Sep. 30, 2020			$ 246,000	266,665,000	(239,375,000)	27,536,000
Balance, shares at Sep. 30, 2020	26	51	24,551,059
Balance at Mar. 31, 2020			$ 118,000	243,999,000	(232,909,000)	11,208,000
Balance, shares at Mar. 31, 2020	249	232	11,778,746
Common stock issued for cash, net of fees			$ 65,000	9,583,000		9,648,000
Common stock issued for cash, net of fees, shares			6,454,381
Extinguishment of derivative liability upon exercise of warrant				1,451,000		1,451,000
Issuance of common stock from the exercise of warrants for cash			$ 6,000	$ 911,000		$ 917,000
Issuance of common stock from the exercise of warrants for cash, shares			611,868
Issuance of common stock from the cashless exercise of warrants			$ 3,000	$ (3,000)
Issuance of common stock from the cashless exercise of warrants, shares			373,750
Common stock issued on conversion of preferred stock			$ 2,000	$ (2,000)
Common stock issued on conversion of preferred stock, shares	(123)	(179)	212,168
Accretion of convertible preferred stock discount				$ 207,000		$ 207,000
Deemed dividend related to the conversion of preferred stock				(207,000)		(207,000)
Net loss					(4,028,000)	(4,028,000)
Balance at Jun. 30, 2020			$ 194,000	255,939,000	(236,937,000)	19,196,000
Balance, shares at Jun. 30, 2020	126	53	19,430,913
Stock based compensation				29,000		29,000
Common stock issued for cash, net of fees			$ 50,000	10,318,000		10,368,000
Common stock issued for cash, net of fees, shares			4,915,000
Extinguishment of derivative liability upon exercise of warrant				190,000		190,000
Issuance of common stock from the exercise of warrants for cash			$ 1,000	190,000		191,000
Issuance of common stock from the exercise of warrants for cash, shares			127,650
Issuance of common stock from the cashless exercise of warrants
Issuance of common stock from the cashless exercise of warrants, shares			1,890
Common stock issued on conversion of preferred stock			$ 1,000	$ (1,000)
Common stock issued on conversion of preferred stock, shares	(100)	(2)	75,606
Issuance of agent warrants
Beneficial conversion feature on issuance of convertible preferred stock
Deemed dividend related to the issuance of preferred stock
Accretion of convertible preferred stock discount				$ 74,000		$ 74,000
Deemed dividend related to the conversion of preferred stock				(74,000)		(74,000)
Net loss					(2,438,000)	(2,437,000)
Balance at Sep. 30, 2020			$ 246,000	$ 266,665,000	$ (239,375,000)	$ 27,536,000
Balance, shares at Sep. 30, 2020	26	51	24,551,059

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash Flow From Operating Activities
Net loss	$ (5,296)	$ (3,805)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	54	79
Amortization of right of use asset	310	264
Amortization of intangible assets	4	4
Non-cash interest income	(242)	(344)
Stock based compensation	29	2
Change in fair value of derivative liabilities	(1,750)	(754)
Offering Costs	325
Bad debt expense		(3)
Changes in operating assets and liabilities:
Trade accounts receivable	87	154
Prepaid expenses and other current assets	(73)	33
Inventories	104	(35)
Accounts payable and accrued liabilities	(353)	83
Payments on operating lease liability	(254)	(557)
Net cash used in operating activities	(7,055)	(4,879)
Cash Flows From Investing Activities
Purchase of property and equipment	(151)	(141)
Proceeds from notes receivable, net of imputed interest	1,528	1,111
Net cash provided by investing activities	1,377	970
Cash Flows From Financing Activities
Proceeds from issuance of warrant derivative liabilities	6,328	103
Proceeds from issuance of common stock, net of fees	20,015	1,285
Proceeds from issuance of preferred stock, net of fees	3,112
Proceeds from issuance of common stock in connection with exercise of warrants	1,109
Proceeds from issuance of debt	406
Principal payments on debt	(29)
Net cash provided by financing activities	30,941	1,388
Net increase (decrease) in cash and cash equivalents	25,263	(2,521)
Cash and cash equivalents at beginning of period	1,787	5,447
Cash and cash equivalents at end of period	27,050	2,926
Noncash Investing and Financing Activities
Reduction of derivative liability due to exercise of warrants	3,197	44
Change in par value due to conversion of preferred stock to common stock	65
Issuance of Common Stock for the Cashless Exercise of Warrants	35
Right-of-use assets and assumption of operating lease liability		2,704
Supplemental Cash Flow Information
Cash paid for interest	$ 2	$ 2

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

1. Organization and Summary of Significant Accounting Policies

Organization

Reverse Stock Split

Basis of Presentation

Use of Estimates

Liquidity and Capital Resources

Risks Related to COVID-19 Pandemic

New Accounting Pronouncements Not Yet Adopted

XML 18 R8.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Income (Loss) Per Common Share

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Basic and Diluted Net Income (Loss) Per Common Share

2. Basic and Diluted Net Income (Loss) per Common Share

Below are basic and diluted loss per share data for the three months ended September 30, 2020, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities		Diluted Calculation
Numerator:
Net loss	$	(2,437	)	$	-	$	(2,437	)
Deemed dividend and accretion of a discount		(74	)		-		(74	)
Net loss attributable to common stockholders	$	(2,511	)	$	-	$	(2,511	)

Denominator:
Number of shares used in per common share calculations:		22,774,263			-		22,774,263

Net loss per common share:
Net loss	$	(0.11	)	$	-	$	(0.11	)
Deemed dividend and accretion of a discount		-			-		-
Net loss attributable to common stockholders	$	(0.11	)	$	-	$	(0.11	)

Below are basic and diluted loss per share data for the nine months ended September 30, 2020, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(5,296	)	$	(2,073	)	$	(7,369	)
Deemed dividend and accretion of a discount		(9,565	)		-			(9,565	)
Net loss attributable to common stockholders	$	(14,861	)	$	(2,073	)	$	(16,934	)

Denominator:
Number of shares used in per common share calculations:		13,671,866			1,422,410			15,094,276

Net income (loss) per common share:
Net loss	$	(0.39	)	$	(0.10	)	$	(0.49	)
Deemed dividend and accretion of a discount		(0.70	)		0.07			(0.63	)
Net income (loss) attributable to common stockholders	$	(1.09	)	$	(0.03	)	$	(1.12	)

Below are basic and diluted loss per share data for the three months ended September 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(1,446	)	$	(144	)	$	(1,590	)
Deemed dividend and accretion of a discount		(345	)		-			(345	)
Net loss attributable to common stockholders	$	(1,791	)	$	(144	)	$	(1,935	)

Denominator:
Number of shares used in per common share calculations:		2,127,293			-			2,127,293

Net loss per common share:
Net loss	$	(0.68	)	$	(0.07	)	$	(0.75	)
Deemed dividend and accretion of a discount		(0.16	)		-			(0.16	)
Net loss attributable to common stockholders	$	(0.84	)	$	(0.07	)	$	(0.91	)

Below are basic and diluted loss per share data for the nine months ended September 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(3,805	)	$	(753	)	$	(4,558	)
Deemed dividend and accretion of a discount		(2,703	)		-			(2,703	)
Net loss attributable to common stockholders	$	(6,508	)	$	(753	)	$	(7,261	)

Denominator:
Number of shares used in per common share calculations:		1,269,106			-			1,269,106

Net loss per common share:
Net loss	$	(3.00	)	$	(0.59	)	$	(3.59	)
Deemed dividend and accretion of a discount		(2.13	)		-			(2.13	)
Net loss attributable to common stockholders	$	(5.13	)	$	(0.59	)	$	(5.72	)

XML 19 R9.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Sep. 30, 2020

Inventory Disclosure [Abstract]

Inventories

3. Inventories

Inventories consisted of the following (in thousands):

	September 30, 2020		December 31, 2019
Raw materials	$	461	$	533
WIP		72		106
Finished Goods		2		-
	$	535	$	639

XML 20 R10.htm IDEA: XBRL DOCUMENT

Intangible Assets

9 Months Ended

Sep. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

4. Intangible Assets

Intangible assets consisted of the following (in thousands):

	September 30, 2020			December 31, 2019
Trademarks	$	50		$	50
Less: accumulated amortization		(13	)		(9	)
	$	37		$	41

Amortization expense for the nine months ended September 30, 2020, was approximately $4.0 thousand. Amortization expense for the nine months ended September 30, 2019, was approximately $4.0 thousand.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

5. Fair Value Measurements

Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis

	Level 1 -	quoted market prices for identical assets or liabilities in active markets.

	Level 2 -	observable prices that are based on inputs not quoted on active markets but corroborated by market data.

	Level 3 -	unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

	Fair Value Measurements as of September 30, 2020
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	1,600	$	1,600

	Fair Value Measurements as of December 31, 2019
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	220	$	220

The Company did not have any transfers of assets and liabilities between any levels of the fair value measurement hierarchy during the nine months ended September 30, 2020 and 2019 (in thousands).

	Common Stock Warrants
Balance as of December 31, 2018	$	(1,566	)
Change in fair value		754
Exercise of warrants		44
Other, net		(1	)
Balance as of September 30, 2019	$	(769	)

Balance as of December 31, 2019	$	(220	)
Issuance of derivatives		(6,328	)
Change in fair value		1,750
Exercise of warrants		3,197
Other, net		1
Balance as of September 30, 2020	$	(1,600	)

Common Stock Warrants

The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. As of September 30, 2020, and December 31, 2019, the derivative liability was calculated using the Monte Carlo Simulation valuation.

The assumptions used in estimating the common stock warrant liability as of September 30, 2020 and December 31, 2019 were as follows:

	September 30, 2020			December 31, 2019
Weighted-average risk-free interest rate		0.16%-0.28	%		1.62	%
Weighted-average expected life (in years)		2.61-4.36			3.4
Expected dividend yield		-	%		-	%
Weighted-average expected volatility		139.17%-160.7	%		64	%

Other Financial Instruments

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

9 Months Ended

Sep. 30, 2020

Payables and Accruals [Abstract]

Accrued Liabilities

6. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	September 30, 2020		December 31,2019
Payroll and related expense	$	646	$	589
Resterilization and repackaging costs		52		392
Other		248		285
	$	946	$	1,266

XML 23 R13.htm IDEA: XBRL DOCUMENT

Debt

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Debt

7. Debt

Equipment Loan

In September 2019, the Company entered into a debt arrangement with a finance company to purchase equipment. The debt balance was paid in full during the third quarter 2020.

PPP Loan

XML 24 R14.htm IDEA: XBRL DOCUMENT

Equity

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Equity

8. Equity

2020 Rights Offering

2020 Registered Direct Offerings

2019 ATM Stock Offerings

XML 25 R15.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

9. Stock-Based Compensation

A summary of the Company’s outstanding stock option activity for the nine months ended September 30, 2020 is as follows:

	Options		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Intrinsic Value
As of December 31, 2019		377	$	7,446.69		5.3	$	-
Granted		515,017		0.47		10.0		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Expired		-		-		-		-
As of September 30, 2020		515,394	$	5.90		9.6	$	746,774
Exercisable as of September 30, 2020		377	$	7,446.69		4.6	$	-

	Nine Months Ended
	September 30, 2020
Weighted-average risk-free interest rate		0.34	%
Weighted-average expected life (in years)		10.0
Expected dividend yield		-	%
Weighted-average expected volatility		129.69	%

Unrecognized stock-based compensation as of September 30, 2020 is as follows (in thousands):

			Weighted Average
	Unrecognized Stock-Based		Remaining of Recognition
	Compensation		(in years)
Stock options	$	204		2.6

XML 26 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. Commitments and Contingencies

XML 27 R17.htm IDEA: XBRL DOCUMENT

Note Receivable

9 Months Ended

Sep. 30, 2020

Receivables [Abstract]

Note Receivable

11. Note Receivable

XML 28 R18.htm IDEA: XBRL DOCUMENT

Discontinued Operations

9 Months Ended

Sep. 30, 2020

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

12. Discontinued Operations

XML 29 R19.htm IDEA: XBRL DOCUMENT

Leases

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Leases

13. Leases

Operating lease future minimum payments together with the present values as of September 30, 2020, are summarized as follows:

Years Ending December 31,	September 30, 2020
2020	$	124
2021		513
2022		528
2023		544
2024		561
Thereafter		-
Total future minimum lease payments		2,270
Less amounts representing interests		(297	)
Present value of lease liability		1,973

Current-portion of operating lease liability		393
Long-term portion operating lease liability	$	1,580

XML 30 R20.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Organization	Organization SINTX Technologies, Inc. (“SINTX” or “the Company”) was incorporated in the state of Delaware on December 10, 1996. SINTX is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company presently manufactures silicon nitride material and components in its FDA registered and ISO 13485:2016 certified facility. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. The Company’s products are primarily sold in the United States.
Reverse Stock Split	Reverse Stock Split On July 26, 2019 the Company effected a 1 for 30 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock shares, equivalents, and per-share amounts for all periods presented in these condensed financial statements have been adjusted retroactively to reflect the reverse stock split.
Basis of Presentation	Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company. In May 2020, the Company dissolved its wholly owned subsidiary ST Sub, Inc. At the time of dissolution the subsidiary had no assets, liabilities, equity, or operations. The financial statements after May 8, 2020, are not consolidated. SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 26, 2020. The results of operations for the nine months ended September 30, 2020, are not necessarily indicative of the results to be expected for the year ending December 31, 2020. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2019.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. As of September 30, 2020, the most significant estimates relate to inventory, long-lived and intangible assets, the liability for preferred stock and common stock warrants, and the derivative liabilities.
Liquidity and Capital Resources	Liquidity and Capital Resources The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements. For the nine months ended September 30, 2020 and 2019, the Company incurred a net loss of $5.3 million and $3.8 million, respectively, and used cash in operations of $7.1 million and $4.9 million, respectively. The Company had an accumulated deficit of $239 million and $234 million as of September 30, 2020 and December 31, 2019, respectively. To date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operations or obtain additional financing is uncertain. The Company is actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of our silicon nitride material are not well known, and we believe the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications. The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering in February 2014. On February 6, 2020, the Company closed on a rights offering to its stockholders of units, consisting of convertible preferred stock and warrants, for gross proceeds of $9.4 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company of approximately $1.2 million. Additionally, during the period of June 2020 through August 2020, the Company closed four registered direct offerings of shares of its common stock, priced at-the-market under Nasdaq rules, resulting in the issuance of a total of 11,015,000 shares of its common stock for gross proceeds of approximately $20.9 million, before considering issuance costs of approximately $1.6 million (see Note 8). During the year ended December 31, 2019, the Company entered into an at-the-market (ATM) equity distribution agreement in which the Company may sell, from time to time, shares of common stock having an aggregate offering price of up to $2.5 million. The Company sold 527,896 shares during the year ended December 31, 2019, raising approximately $1.7 million before deducting fees to the placement agent and other offering expenses of approximately $0.2 million. During the nine month period ending September 30, 2020, the Company sold 354,500 shares of common stock, raising approximately $0.8 million deducting fees to the placement agent and other offering expenses of approximately $0.034 million. As of September 30, 2020, no funding capacity is available under the ATM. (see Note 8). On October 1, 2018, the Company sold the retail spine business to CTL Medical. The sale included a $6 million noninterest bearing note receivable payable over a 36-month term. The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable to occur October 1, 2021. The Company expects cash flows of approximately $2.5 million for the remaining thirteen months. Management has concluded that together with its existing capital resources and payments on the note receivable from the sale of the Spine business will be sufficient to fund operations for at least the next 12 months, or through November 2021. In the financial statements for the year ended December 31, 2019, the Company concluded substantial doubt existed for the Company to continue as a going concern. Beginning with the period ended March 31, 2020, the Company’s position changed as a result of the capital raises outlined in Note 8.
Risks Related to COVID-19 Pandemic	Risks Related to COVID-19 Pandemic The recent outbreak of COVID-19 originated in Wuhan, China, in December 2019 and has since spread to multiple countries, including the United States and several European countries. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which we rely.
New Accounting Pronouncements Not Yet Adopted	New Accounting Pronouncements Not Yet Adopted The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements.

XML 31 R21.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Income (Loss) per Common Share (Tables)

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Loss Per Share

Below are basic and diluted loss per share data for the three months ended September 30, 2020, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities		Diluted Calculation
Numerator:
Net loss	$	(2,437	)	$	-	$	(2,437	)
Deemed dividend and accretion of a discount		(74	)		-		(74	)
Net loss attributable to common stockholders	$	(2,511	)	$	-	$	(2,511	)

Denominator:
Number of shares used in per common share calculations:		22,774,263			-		22,774,263

Net loss per common share:
Net loss	$	(0.11	)	$	-	$	(0.11	)
Deemed dividend and accretion of a discount		-			-		-
Net loss attributable to common stockholders	$	(0.11	)	$	-	$	(0.11	)

Below are basic and diluted loss per share data for the nine months ended September 30, 2020, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(5,296	)	$	(2,073	)	$	(7,369	)
Deemed dividend and accretion of a discount		(9,565	)		-			(9,565	)
Net loss attributable to common stockholders	$	(14,861	)	$	(2,073	)	$	(16,934	)

Denominator:
Number of shares used in per common share calculations:		13,671,866			1,422,410			15,094,276

Net income (loss) per common share:
Net loss	$	(0.39	)	$	(0.10	)	$	(0.49	)
Deemed dividend and accretion of a discount		(0.70	)		0.07			(0.63	)
Net income (loss) attributable to common stockholders	$	(1.09	)	$	(0.03	)	$	(1.12	)

Below are basic and diluted loss per share data for the three months ended September 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(1,446	)	$	(144	)	$	(1,590	)
Deemed dividend and accretion of a discount		(345	)		-			(345	)
Net loss attributable to common stockholders	$	(1,791	)	$	(144	)	$	(1,935	)

Denominator:
Number of shares used in per common share calculations:		2,127,293			-			2,127,293

Net loss per common share:
Net loss	$	(0.68	)	$	(0.07	)	$	(0.75	)
Deemed dividend and accretion of a discount		(0.16	)		-			(0.16	)
Net loss attributable to common stockholders	$	(0.84	)	$	(0.07	)	$	(0.91	)

Below are basic and diluted loss per share data for the nine months ended September 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Net loss	$	(3,805	)	$	(753	)	$	(4,558	)
Deemed dividend and accretion of a discount		(2,703	)		-			(2,703	)
Net loss attributable to common stockholders	$	(6,508	)	$	(753	)	$	(7,261	)

Denominator:
Number of shares used in per common share calculations:		1,269,106			-			1,269,106

Net loss per common share:
Net loss	$	(3.00	)	$	(0.59	)	$	(3.59	)
Deemed dividend and accretion of a discount		(2.13	)		-			(2.13	)
Net loss attributable to common stockholders	$	(5.13	)	$	(0.59	)	$	(5.72	)

XML 32 R22.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

9 Months Ended

Sep. 30, 2020

Inventory Disclosure [Abstract]

Schedule of Components of Inventory

Inventories consisted of the following (in thousands):

	September 30, 2020		December 31, 2019
Raw materials	$	461	$	533
WIP		72		106
Finished Goods		2		-
	$	535	$	639

XML 33 R23.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets consisted of the following (in thousands):

	September 30, 2020			December 31, 2019
Trademarks	$	50		$	50
Less: accumulated amortization		(13	)		(9	)
	$	37		$	41

XML 34 R24.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy

The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of September 30, 2020 and December 31, 2019 (in thousands):

	Fair Value Measurements as of September 30, 2020
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	1,600	$	1,600

	Fair Value Measurements as of December 31, 2019
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	220	$	220

Schedule of Fair Value Measurement Hierarchy of Derivative Liability

The Company did not have any transfers of assets and liabilities between any levels of the fair value measurement hierarchy during the nine months ended September 30, 2020 and 2019 (in thousands).

	Common Stock Warrants
Balance as of December 31, 2018	$	(1,566	)
Change in fair value		754
Exercise of warrants		44
Other, net		(1	)
Balance as of September 30, 2019	$	(769	)

Balance as of December 31, 2019	$	(220	)
Issuance of derivatives		(6,328	)
Change in fair value		1,750
Exercise of warrants		3,197
Other, net		1
Balance as of September 30, 2020	$	(1,600	)

Schedule of Assumptions Used in Estimating Fair Value

The assumptions used in estimating the common stock warrant liability as of September 30, 2020 and December 31, 2019 were as follows:

	September 30, 2020			December 31, 2019
Weighted-average risk-free interest rate		0.16%-0.28	%		1.62	%
Weighted-average expected life (in years)		2.61-4.36			3.4
Expected dividend yield		-	%		-	%
Weighted-average expected volatility		139.17%-160.7	%		64	%

XML 35 R25.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2020

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	September 30, 2020		December 31,2019
Payroll and related expense	$	646	$	589
Resterilization and repackaging costs		52		392
Other		248		285
	$	946	$	1,266

XML 36 R26.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

Summary of Stock Option Activity

A summary of the Company’s outstanding stock option activity for the nine months ended September 30, 2020 is as follows:

	Options		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Intrinsic Value
As of December 31, 2019		377	$	7,446.69		5.3	$	-
Granted		515,017		0.47		10.0		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Expired		-		-		-		-
As of September 30, 2020		515,394	$	5.90		9.6	$	746,774
Exercisable as of September 30, 2020		377	$	7,446.69		4.6	$	-

Schedule of Assumption Used for Fair value of Option

The following weighted average assumptions were used in the calculation to estimate the fair value of options granted to employees during the nine months ended September 30, 2020.

	Nine Months Ended
	September 30, 2020
Weighted-average risk-free interest rate		0.34	%
Weighted-average expected life (in years)		10.0
Expected dividend yield		-	%
Weighted-average expected volatility		129.69	%

Schedule of Unrecognized Stock-based Compensation

Unrecognized stock-based compensation as of September 30, 2020 is as follows (in thousands):

			Weighted Average
	Unrecognized Stock-Based		Remaining of Recognition
	Compensation		(in years)
Stock options	$	204		2.6

XML 37 R27.htm IDEA: XBRL DOCUMENT

Leases (Tables)

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Schedule of Operating Lease Future Minimum Payments

Operating lease future minimum payments together with the present values as of September 30, 2020, are summarized as follows:

Years Ending December 31,	September 30, 2020
2020	$	124
2021		513
2022		528
2023		544
2024		561
Thereafter		-
Total future minimum lease payments		2,270
Less amounts representing interests		(297	)
Present value of lease liability		1,973

Current-portion of operating lease liability		393
Long-term portion operating lease liability	$	1,580

XML 38 R28.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands					3 Months Ended						9 Months Ended		12 Months Ended
	Feb. 06, 2020	Sep. 12, 2019	Jul. 26, 2019	Oct. 02, 2018	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Reverse stock split			1 for 30 reverse stock split
Net loss					$ (2,437)	$ (4,028)	$ 1,169	$ (1,446)	$ (730)	$ (1,629)	$ (5,296)	$ (3,805)
Net cash used in operating activities											(7,055)	$ (4,879)
Accumulated deficit					$ (239,375)						(239,375)		$ (234,078)
Proceeds from issuance of public offering	$ 9,400
Underwriting discounts and commissions and offering expenses payable	$ 1,200
Non interest note receivable				$ 6,000
Debt description				The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable on October 1, 2021
Maturity date of note receivable				Oct. 01, 2021
Following 18-Month Payment Period [Member]
Proceeds from notes receivable											$ 2,500
Two Registered Direct Offerings [Member]
Number of shares issuance cost											11,015,000
Proceeds from issuance cost											$ 20,900
Stock offering expense											$ 1,600
ATM Equity Distribution Agreement [Member]
Proceeds from issuance of public offering		$ 2,500
Number of stock sold during period											354,500		527,896
Sale of stock value											$ 800		$ 1,700
Stock offering expense											$ 34		200
ATM Equity Distribution Agreement [Member] \| Maximum [Member]
Proceeds from issuance of public offering		$ 2,500											$ 2,500

XML 39 R29.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Income (Loss) Per Common Share (Details Narrative) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Potentially dilutive securities	1,600,000	500,000

XML 40 R30.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Income (Loss) Per Common Share - Schedule of Basic and Diluted Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Net loss	$ (2,437)	$ (4,028)	$ 1,169	$ (1,446)	$ (730)	$ (1,629)	$ (5,296)	$ (3,805)
Deemed dividend and accretion of a discount, basic calculation	(74)			(345)			(9,565)	(2,703)
Net loss attributable to common stockholders, basic calculation	$ (2,511)			$ (1,791)			$ (14,861)	$ (6,508)
Number of shares used in per common share calculations: basic calculation	22,774,263			2,127,293			13,671,866	1,269,106
Net loss, basic calculation	$ (0.11)			$ (0.68)			$ (0.39)	$ (3.00)
Deemed dividend and accretion of a discount, basic calculation				(0.16)			(0.70)	(2.13)
Net income (loss) attributable to common stockholders, basic calculation	$ (0.11)			$ (0.84)			$ (1.09)	$ (5.13)
Net income (loss), effect of dilutive warrant securities				$ (144)			$ (2,073)	$ (753)
Deemed dividend and accretion of a discount, effect of dilutive warrant securities
Net loss attributable to common stockholders, effect of dilutive warrant securities				$ (144)			$ (2,073)	$ (753)
Number of shares used in per common share calculations: effect of dilutive warrant securities							1,422,410
Net income, effect of dilutive warrant securities				$ (0.07)			$ (0.10)	$ (0.59)
Deemed dividend and accretion of a discount, effect of dilutive warrant securities							(0.07)
Net loss attributable to common stockholders, effect of dilutive warrant securities				$ (0.07)			$ (0.03)	$ (0.59)
Net income (loss), diluted calculation	$ (2,437)			$ (1,590)			$ (7,369)	$ (4,558)
Deemed dividend and accretion of a discount, diluted calculation	(74)			(345)			(9,565)	(2,703)
Net loss attributable to common stockholders, diluted calculation	$ (2,511)			$ (1,935)			$ (16,934)	$ (7,261)
Number of shares used in per common share calculations: diluted calculation	22,774,263			2,127,293			15,094,276	1,269,106
Net income (loss), diluted calculation	$ (0.11)			$ (0.75)			$ (0.49)	$ (3.59)
Deemed dividend and accretion of a discount, diluted calculation				(0.16)			(0.63)	(2.13)
Net loss attributable to common stockholders, diluted calculation	$ (0.11)			$ (0.91)			$ (1.12)	$ (5.72)

XML 41 R31.htm IDEA: XBRL DOCUMENT

Inventories (Details Narrative) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventory, current	$ 74	$ 106
Inventory, non-current	$ 461	$ 533

XML 42 R32.htm IDEA: XBRL DOCUMENT

Inventories - Schedule of Components of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 461	$ 533
WIP	72	106
Finished Goods	2
Inventory	$ 535	$ 639

XML 43 R33.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details Narrative) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 4	$ 4

XML 44 R34.htm IDEA: XBRL DOCUMENT

Intangible Assets - Schedule of Intangible Assets (Details) - Trademarks [Member] - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 50	$ 50
Less: accumulated amortization	(13)	(9)
Intangible assets, net	$ 37	$ 41

XML 45 R35.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy (Details) - Fair Value, Measurements, Recurring [Member] - Common Stock Warrants [Member] - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 1,600	$ 220
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 1,600	$ 220

XML 46 R36.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Fair Value Measurement Hierarchy of Derivative Liability (Details) - Common Stock Warrants [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Beginning balance	$ (220)	$ (1,566)
Issuance of derivatives	(6,328)
Change in fair value	1,750	754
Exercise of warrants	3,197	44
Other, net	1	(1)
Ending balance	$ (1,600)	$ (769)

XML 47 R37.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Assumptions Used in Estimating Fair Value (Details) - Common Stock Warrants [Member] - Black-Scholes-Merton Valuation Model [Member]	Sep. 30, 2020	Dec. 31, 2019
Weighted-Average Risk-Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages		1.62
Weighted-Average Risk-Free Interest Rate [Member] \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	0.16
Weighted-Average Risk-Free Interest Rate [Member] \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	0.28
Weighted-Average Expected Life (in years) [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term		3 years 4 months 24 days
Weighted-Average Expected Life (in years) [Member] \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term	2 years 7 months 10 days
Weighted-Average Expected Life (in years) [Member] \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term	4 years 4 months 9 days
Expected Dividend Yield [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	0.00	0.00
Weighted Average Expected Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages		64
Weighted Average Expected Volatility [Member] \| Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	139.17
Weighted Average Expected Volatility [Member] \| Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	160.7

XML 48 R38.htm IDEA: XBRL DOCUMENT

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Payroll and related expense	$ 646	$ 589
Resterilization and repackaging costs	52	392
Other	248	285
Total accrued liabilities	$ 946	$ 1,266

XML 49 R39.htm IDEA: XBRL DOCUMENT

Debt (Details Narrative) - USD ($) $ in Thousands	Apr. 28, 2020	Oct. 02, 2018	Oct. 31, 2018
Debt instrument, interest rate			10.00%
Debt instrument, maturity date		Oct. 01, 2021
PPP Loan [Member] \| PPP Loan [Member]
Debt principal amount	$ 391
Debt instrument, interest rate	1.00%
Debt instrument term	2 years
Debt instrument, maturity date	Apr. 28, 2022
Debt forgiven amount percentage	60.00%

XML 50 R40.htm IDEA: XBRL DOCUMENT

Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands								1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
	Aug. 04, 2020	Jul. 16, 2020	Jun. 26, 2020	Jun. 23, 2020	Feb. 06, 2020	Sep. 12, 2019	Jun. 04, 2019	Feb. 29, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Sep. 12, 2020	Oct. 31, 2018
Number of share units issued for conversion
Gross proceeds of warrants exercise												$ 1,109
Proceeds from issuance of units												$ 3,112
Underwriting discounts and commissions and offering expenses payable					$ 1,200
Common stock, par value									$ 0.01			$ 0.01		$ 0.01
Proceeds from common stock												$ 20,015	$ 1,285
Proceeds from public offering					$ 9,400
Debt instrument, interest rate																10.00%
Two Registered Direct Offerings [Member]
Number of shares issuance cost												6,100,000
Proceeds from issuance cost												$ 9,600
Net issuance fees												1,600
Share Purchase Agreement [Member]
Purchase price per units	$ 2.40	$ 2.00	$ 1.72	$ 1.50
Number of shares of common stock	3,415,000	1,500,000	2,400,000	3,700,000
Common stock, par value	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Proceeds from common stock	$ 8,200	$ 3,000	$ 4,100	$ 5,500
ATM Equity Distribution Agreement [Member]
Proceeds from public offering						$ 2,500
Debt instrument, interest rate															4.25%
Sale of stock value												800		$ 1,700
Net issuance fees												$ 34		$ 200
Sale of stock, shares												354,500		527,896
ATM Equity Distribution Agreement [Member] \| Maximum [Member]
Common stock offering price							$ 1,600
Proceeds from public offering						2,500								$ 2,500
ATM Equity Distribution Agreement [Member] \| Minimum [Member]
Proceeds from public offering						$ 1,600
Holders of Warrants One [Member]
Warrant exercised during period												5,006,475
Holders of Warrants Two [Member]
Warrant exercised during period												739,618
Holders of Warrants [Member]
Gross proceeds of warrants exercise												$ 1,100
Series C Preferred Stock Purchase Warrant [Member]
Warrants to purchase of common stock shares								675
Conversion price, description								Company's option at any time on or after the first anniversary of the expiration of the rights offering or at the option of the holder at any time, into a number of shares of our common stock equal to the quotient of the stated value of the Preferred Stock ($1,000) divided by the Conversion Price ($1.4814 per share).
Purchase price per units								$ 1,000
Conversion price per share								$ 1.4814
Warrants description								Each Warrant is exercisable for one share of our common stock at an exercise price of $1.50 per share from the date of issuance through its expiration five years from the date of issuance. The Warrants also contain a cashless exercise provision that allows the holder to receive 70% of the common stock otherwise available under the warrant to the holder electing the cashless exercise provision.
Warrants exercise price								$ 1.50
Number of share units issued for conversion								9,440
Gross proceeds of warrants exercise								$ 9,400
Issuance cost, total								$ 1,200
Warrants Exercisable [Member]
Number of share units issued for conversion								6,372,000
Proceeds from issuance of units								$ 5,100
Warrants issuance cost								$ 1,200
Preferred Shares [Member]
Number of share units issued for conversion								6,372,350
Proceeds from issuance of units								$ 3,100
Preferred stock issuance costs
Common Stock [Member]
Number of share units issued for conversion									75,606	212,168	6,215,742
Common Stock [Member] \| Holders of Warrants One [Member]
Number of share units issued for conversion												3,504,535
Common Stock [Member] \| Holders of Warrants Two [Member]
Number of share units issued for conversion												739,618
Common Stock [Member] \| Series B Convertible Preferred Stock [Member]
Number of share units issued for conversion												165,586
Conversion of convertible shares												223
Common Stock [Member] \| Series C Convertible Preferred Stock [Member]
Number of share units issued for conversion												6,337,930
Conversion of convertible shares												9,389

XML 51 R41.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details Narrative) - 2020 [Member] - Board of Directors [Member]	9 Months Ended
	Sep. 30, 2020 shares
Number of common stock issued	1,902,520
Common Stock from Paln amended	2,520

XML 52 R42.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2020 USD ($) $ / shares shares
Share-based Payment Arrangement [Abstract]
Options outstanding at begining \| shares	377
Options, granted \| shares	515,017
Options, exercised \| shares
Options, forfeited \| shares
Options, expired \| shares
Options, outstanding at end \| shares	515,394
Options, exercisable at end \| shares	377
Weighted average exercisable price \| $ / shares	$ 7,446.69
Weighted average exercise erice, granted \| $ / shares	0.47
Weighted average exercise price, exercised \| $ / shares
Weighted average exercise price, forfeited \| $ / shares
Weighted average exercise price, expired \| $ / shares
Weighted average exercise price, outstanding at end of period \| $ / shares	5.90
Weighted average exercise price, exercisable at end of period \| $ / shares	$ 7,446.69
Weighted average remaining contractual terms (years), outstanding at beginning	5 years 3 months 19 days
Weighted average remaining contractual terms (years), granted	10 years
Weighted average remaining contractual terms (years), outstanding at ending	9 years 7 months 6 days
Weighted average remaining contractual terms (years), exercisable	4 years 7 months 6 days
Intrinsic value, outstanding at beginning of period \| $
Intrinsic value, outstanding at end of period \| $	746,774
Intrinsic value, exercisable at end of period \| $

XML 53 R43.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Assumption Used for Fair value of Option (Details)	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Weighted-average risk-free interest rate	0.0034
Weighted-average expected life (in years)	10 years
Expected dividend yield	0.000
Weighted-average expected volatility	129.69%

XML 54 R44.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Unrecognized Stock-Based Compensation (Details) - Employee Stock Option [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2020 USD ($)
Unrecognized stock-based compensation	$ 204
Weighted average remaining period of recognition (in years)	2 years 7 months 6 days

XML 55 R45.htm IDEA: XBRL DOCUMENT

Note Receivable (Details Narrative) - USD ($) $ in Thousands		9 Months Ended
	Oct. 02, 2018	Sep. 30, 2020	Dec. 31, 2019	Oct. 31, 2018
Non interest note receivable	$ 6,000
Debt description	The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable on October 1, 2021
Maturity date of note receivable	Oct. 01, 2021
Debt instrument, interest rate				10.00%
Imputed interest				$ 915,725
Imputed interest, description	The note receivable includes an imputed interest rate of 10%, which totaled $915,725 as of October 31, 2018, and has a 36-month amortization.
Notes receivable		$ 2,189	$ 1,724
Total consideration		$ 2,500
First Payment [Member]
Payments of notes receivable	$ 138,889
Second Payment [Member]
Payments of notes receivable	$ 194,444

XML 56 R46.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Details Narrative) - USD ($) $ in Thousands		9 Months Ended
	Oct. 02, 2018	Sep. 30, 2020
Total consideration		$ 2,500
Asset Purchase Agreement [Member]
Total consideration	$ 8,500
Sterilization and repackaging cost		$ 100
Asset Purchase Agreement [Member] \| Related Party Note Payable [Member]
Total consideration	2,500
Asset Purchase Agreement [Member] \| Interest Note Receivable [Member]
Total consideration	$ 6,000

XML 57 R47.htm IDEA: XBRL DOCUMENT

Leases (Details Narrative) $ in Thousands		9 Months Ended
Leases (Details Narrative) $ in Thousands	Jun. 07, 2019 ft²	Sep. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)
Leases [Abstract]
Lease expired, description		The Company leases office, warehouse and manufacturing space under a single operating lease.
Lease extended period, description	On June 7, 2019, the lease was amended to extend the rental period through 2024	The amended lease has two five-year extension options.
Area of lease \| ft²	54,428
Reduction of lease area \| ft²	29,732
Operating lease right-of-use asset		$ 2,031	$ 2,341
Operating lease liability		1,973
Non-cash lease expense		$ 300
Operating lease weighted-average discount rate		6.50%

XML 58 R48.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Operating Lease Future Minimum Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Leases [Abstract]
2020	$ 124
2021	513
2022	528
2023	544
2024	561
Thereafter
Total future minimum lease payments	2,270
Less amounts representing interests	(297)
Present value of lease liability	1,973
Current-portion of operating lease liability	393	$ 360
Long-term portion operating lease liability	$ 1,580	$ 1,867

EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:GGS1MYO+;^YMNYJ8>V5^-W4QD^2=0B;T]'(EVO52/_";I2!,TOK M&AG@T*U&?N.4K/Q:J=#4HVP\/ADU4IOD[9O=6-_<"!_8H,J@K8'&KN%2JVO_ M]WQW*+;:ZX6N=;B9)/%[K1+1:*,;?:NJ23).A%_;ZR_6Z5MK@JSGI;-U/4G2 M_L2E0/N?"Q)K(C@? MY =K*F6\J@1\\[;6%7!4XKVLI2F50) 9 9D](>3/#$'F!&3^))#S#@=^BB + M K)X0LA!)(\)R..GA,P1Y D!><(+>>%6TNC;>"+>X?.V::2[$78IYGJ%(%\2 MD"]Y(=]+K\M(-]5UVP7Q'&::F=(V2CP[0Y"O",A7O) SLX4.8 CE$=!K N@U M-U"09M7-*=YY#Y; J7I,Y>HQ+]@GJ9VXE'6KQ%NZQ#+$(U7"[))W9>E: M6&-G6L::8/B'II1 4F:#3-4B8!;*$RFS*#[^:J$4P#24$%)F(\R#+:^.(%'$ M=-O 2/Y!>4*Y(&670=/H$-=Y3&2@A 5G3+EO>5%N2!EEL$YE,KBNRJ5WLHX M\U\L*ONGS.E_JGT9P]7=E1<;Y?HN&(_*^RESXC^#'#;\#ZFDGS)G?5+H@](H MHQR0,3N 5/H0DW)!QNP")'7Q[$=W4_CGF(U\FF"6P0._[R6D%)$Q*^* Z'>< M&)-R1\;LCCW"WQM*RA\9LS\.^>T.%&-2!LF8#=+GPKW1HPR2,1N$3HKX42RC M3)(QFX1.B@-,2C$9LV)HS +O8U"*R9D5,\C=4Q6DKKTXEZXK'[8*K\V<4DS^ MB(HY$G,8L6HAI@MD\%"8, MCS$I\Q3,YB$Q![FR(-^<,)OGWA[/_=L(8U+F*9C-+,2GS%(_TO$/G M(DHZ!;-T[@B'E>5=0,T*2Z>@I%-$Z8QVKYLKM=1&5>ZCWZ/ MO#CN-L&6;5U_@+8+<%&2+*"6N $ M .<< : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V3MNPD 4A>&M M("^ X3X@(8)4:=)&;,""X2$>MCP3!78?! 4I_"8 N!V()D"X'9 M@F@+@=J"; N!VX)P"X'<@G0+@=V"> N!WHIZ*X'>BGHK@=[Z\+%-H+>BWDJ@ MMZ+>2J"WHMY*H+>BWDJ@MZ+>2J"WHMY*H+>BWDJ@MZ'>1J"WH=Y&H+>AWD:@ MMSTAMJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z&VHMQ'H[:BW$^CMJ+<3 MZ.VHMQ/H[:BW$^CM#X?=!'H[ZNT$>COJ[01Z.^KM!'H[ZNW/U#OETRZF6\]U MC>]_)M7Y_&R\O?ZRO&ZBA,,+S@'^:[[_ E!+ P04 " #Z7G!1C$_JC[H! M #N' $P %M#;VYT96YT7U1Y<&5S72YX;6S-VUW7VSI;#)^VUKRO4U= M-7Z2%"'8!\9\5E"M?6HL-7%D;ERM0WQT"V9UMM0+8F(X'+',-(&:, AMC60Z M?J*Y7E6A][R)KWUIFDGBJ/))[W$WL3?4@;[A#2N[.;X MHK2^'RC3S>9E1 M;K)5'9>DWCK2N2^(0EVENZ+]\\DA[C#MKOSJ_*[,N< X<^:,]?'$'%T>=SB2 M=O7 QD+D0GG^$X^)L?35WT?M:>>4_S([;N^'<X K @ $0 @ &O 9&]C4')O M<',O8V]R92YX;6Q02P$"% ,4 " #Z7G!1F5R<(Q & "<)P $P M @ ', 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( /I> M<%&MXY.2J , L- 8 " @0T( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% M @ ^EYP42[4C'@G P ]0P !@ ("!;1( 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ ^EYP4:@[%0%T!P M^1\ !@ ("!/2T 'AL+W=O<%&<&PO=V]R:W-H965T&UL4$L! A0#% @ ^EYP4:P!KH+. @ '08 !@ M ("!#TL 'AL+W=O M<%$3U2RUD ( -X% 9 " @1-. !X;"]W;W)K&UL4$L! A0#% @ ^EYP45"]G"S@!@ :A( !D M ("!VE 'AL+W=O&PO=V]R M:W-H965T<%%I;6(>J 4 #$, M 9 " @9]: !X;"]W;W)K&UL M4$L! A0#% @ ^EYP4?Q!"AQ@"@ H"$ !D ("!?F M 'AL+W=O&PO=V]R:W-H965T<%&=,[J%6@, "T' 9 M " @5EQ !X;"]W;W)K&UL4$L! A0#% @ M^EYP48^]+/(8 P MP8 !D ("!ZG0 'AL+W=O&PO=V]R:W-H965T<%%. MSCY@:@( P% 9 " @2"7 !X;"]W;W)K&UL4$L! A0#% @ ^EYP423>0Y=Q @ + 4 !D M ("!P9D 'AL+W=O&PO=V]R:W-H M965T<%%S5Y>(@@( $4% 9 M " @2*A !X;"]W;W)K&UL4$L! M A0#% @ ^EYP4;H)=F(5! U D !D ("!VZ, 'AL M+W=O&PO=V]R:W-H965T<%& IU*^S@4 .X6 9 " M@3RK !X;"]W;W)K&UL4$L! A0#% @ ^EYP M44A9&C=- @ ,P4 !D ("!0;$ 'AL+W=O&PO=V]R:W-H965T<%&&R<>9'P( 0% 9 " @2:Z !X;"]W;W)K M&UL4$L! A0#% @ ^EYP46S)]*9T @ 5P8 M !D ("!?+P 'AL+W=O&PO=V]R:W-H965T<%%-!C-3 M8 ( .T% 9 " @:/! !X;"]W;W)K&UL4$L! A0#% @ ^EYP4;U<:>\" P \@H !D M ("!.L0 'AL+W=O&PO=V]R:W-H965T M<%%SW_!3"P0 ,X4 9 M " @9G* !X;"]W;W)K&UL4$L! A0# M% @ ^EYP42=6DE"& @ <@8 !D ("!V\X 'AL+W=O M&PO=V]R:W-H965T<%$[WZR#T@D #XR 9 " @7?4 M !X;"]W;W)K&UL4$L! A0#% @ ^EYP4;_N M)=4R @ MP0 !D ("!@-X 'AL+W=O&PO=V]R:W-H965T<%$/ZKO*F0( &0& 9 " @6CE !X;"]W;W)K&UL4$L! A0#% @ ^EYP43C>+[A= @ *04 !D M ("!..@ 'AL+W=O&PO M=V]R:W-H965T<%$A!10PD0( M %P' 9 " @;/N !X;"]W;W)K&UL4$L! A0#% @ ^EYP42X%S7IU P Y D !D ("! M>_$ 'AL+W=O&PO=V]R:W-H965T<%%(H#(G4P( $0, - M " 7WX !X;"]S='EL97,N>&UL4$L! A0#% @ ^EYP49>*NQS M $P( L ( !^_H %]R96QS+RYR96QS4$L! A0#% M @ ^EYP4=SXL(;W P _1\ \ ( !Y/L 'AL+W=O<%&2+*"6N $ .<< : M " 0@ 0!X;"]?<%&,3^J/N@$ .X< 3 " ?@! 0!;0V]N=&5N=%]4 ?>7!E&UL4$L%!@ X #@ /P\ .,# 0 $! end XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 166 349 1 false 42 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://sintx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://sintx.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://sintx.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://sintx.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://sintx.com/role/StatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://sintx.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://sintx.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share Sheet http://sintx.com/role/BasicAndDilutedNetIncomeLossPerCommonShare Basic and Diluted Net Income (Loss) Per Common Share Notes 8 false false R9.htm 00000009 - Disclosure - Inventories Sheet http://sintx.com/role/Inventories Inventories Notes 9 false false R10.htm 00000010 - Disclosure - Intangible Assets Sheet http://sintx.com/role/IntangibleAssets Intangible Assets Notes 10 false false R11.htm 00000011 - Disclosure - Fair Value Measurements Sheet http://sintx.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 00000012 - Disclosure - Accrued Liabilities Sheet http://sintx.com/role/AccruedLiabilities Accrued Liabilities Notes 12 false false R13.htm 00000013 - Disclosure - Debt Sheet http://sintx.com/role/Debt Debt Notes 13 false false R14.htm 00000014 - Disclosure - Equity Sheet http://sintx.com/role/Equity Equity Notes 14 false false R15.htm 00000015 - Disclosure - Stock-Based Compensation Sheet http://sintx.com/role/Stock-basedCompensation Stock-Based Compensation Notes 15 false false R16.htm 00000016 - Disclosure - Commitments and Contingencies Sheet http://sintx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 00000017 - Disclosure - Note Receivable Sheet http://sintx.com/role/NoteReceivable Note Receivable Notes 17 false false R18.htm 00000018 - Disclosure - Discontinued Operations Sheet http://sintx.com/role/DiscontinuedOperations Discontinued Operations Notes 18 false false R19.htm 00000019 - Disclosure - Leases Sheet http://sintx.com/role/Leases Leases Notes 19 false false R20.htm 00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://sintx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://sintx.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Basic and Diluted Net Income (Loss) per Common Share (Tables) Sheet http://sintx.com/role/BasicAndDilutedNetIncomeLossPerCommonShareTables Basic and Diluted Net Income (Loss) per Common Share (Tables) Tables http://sintx.com/role/BasicAndDilutedNetIncomeLossPerCommonShare 21 false false R22.htm 00000022 - Disclosure - Inventories (Tables) Sheet http://sintx.com/role/InventoriesTables Inventories (Tables) Tables http://sintx.com/role/Inventories 22 false false R23.htm 00000023 - Disclosure - Intangible Assets (Tables) Sheet http://sintx.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://sintx.com/role/IntangibleAssets 23 false false R24.htm 00000024 - Disclosure - Fair Value Measurements (Tables) Sheet http://sintx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://sintx.com/role/FairValueMeasurements 24 false false R25.htm 00000025 - Disclosure - Accrued Liabilities (Tables) Sheet http://sintx.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://sintx.com/role/AccruedLiabilities 25 false false R26.htm 00000026 - Disclosure - Stock-Based Compensation (Tables) Sheet http://sintx.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://sintx.com/role/Stock-basedCompensation 26 false false R27.htm 00000027 - Disclosure - Leases (Tables) Sheet http://sintx.com/role/LeasesTables Leases (Tables) Tables http://sintx.com/role/Leases 27 false false R28.htm 00000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) Sheet http://sintx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Organization and Summary of Significant Accounting Policies (Details Narrative) Details http://sintx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies 28 false false R29.htm 00000029 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share (Details Narrative) Sheet http://sintx.com/role/BasicAndDilutedNetIncomeLossPerCommonShareDetailsNarrative Basic and Diluted Net Income (Loss) Per Common Share (Details Narrative) Details http://sintx.com/role/BasicAndDilutedNetIncomeLossPerCommonShareTables 29 false false R30.htm 00000030 - Disclosure - Basic and Diluted Net Income (Loss) Per Common Share - Schedule of Basic and Diluted Loss Per Share (Details) Sheet http://sintx.com/role/BasicAndDilutedNetIncomeLossPerCommonShare-ScheduleOfBasicAndDilutedLossPerShareDetails Basic and Diluted Net Income (Loss) Per Common Share - Schedule of Basic and Diluted Loss Per Share (Details) Details http://sintx.com/role/BasicAndDilutedNetIncomeLossPerCommonShareTables 30 false false R31.htm 00000031 - Disclosure - Inventories (Details Narrative) Sheet http://sintx.com/role/InventoriesDetailsNarrative Inventories (Details Narrative) Details http://sintx.com/role/InventoriesTables 31 false false R32.htm 00000032 - Disclosure - Inventories - Schedule of Components of Inventory (Details) Sheet http://sintx.com/role/Inventories-ScheduleOfComponentsOfInventoryDetails Inventories - Schedule of Components of Inventory (Details) Details 32 false false R33.htm 00000033 - Disclosure - Intangible Assets (Details Narrative) Sheet http://sintx.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://sintx.com/role/IntangibleAssetsTables 33 false false R34.htm 00000034 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://sintx.com/role/IntangibleAssets-ScheduleOfIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 34 false false R35.htm 00000035 - Disclosure - Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy (Details) Sheet http://sintx.com/role/FairValueMeasurements-ScheduleOfFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy (Details) Details 35 false false R36.htm 00000036 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurement Hierarchy of Derivative Liability (Details) Sheet http://sintx.com/role/FairValueMeasurements-ScheduleOfFairValueMeasurementHierarchyOfDerivativeLiabilityDetails Fair Value Measurements - Schedule of Fair Value Measurement Hierarchy of Derivative Liability (Details) Details 36 false false R37.htm 00000037 - Disclosure - Fair Value Measurements - Schedule of Assumptions Used in Estimating Fair Value (Details) Sheet http://sintx.com/role/FairValueMeasurements-ScheduleOfAssumptionsUsedInEstimatingFairValueDetails Fair Value Measurements - Schedule of Assumptions Used in Estimating Fair Value (Details) Details 37 false false R38.htm 00000038 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) Sheet http://sintx.com/role/AccruedLiabilities-ScheduleOfAccruedLiabilitiesDetails Accrued Liabilities - Schedule of Accrued Liabilities (Details) Details 38 false false R39.htm 00000039 - Disclosure - Debt (Details Narrative) Sheet http://sintx.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://sintx.com/role/Debt 39 false false R40.htm 00000040 - Disclosure - Equity (Details Narrative) Sheet http://sintx.com/role/EquityDetailsNarrative Equity (Details Narrative) Details http://sintx.com/role/Equity 40 false false R41.htm 00000041 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://sintx.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://sintx.com/role/Stock-basedCompensationTables 41 false false R42.htm 00000042 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) Sheet http://sintx.com/role/Stock-basedCompensation-SummaryOfStockOptionActivityDetails Stock-Based Compensation - Summary of Stock Option Activity (Details) Details 42 false false R43.htm 00000043 - Disclosure - Stock-Based Compensation - Schedule of Assumption Used for Fair value of Option (Details) Sheet http://sintx.com/role/Stock-basedCompensation-ScheduleOfAssumptionUsedForFairValueOfOptionDetails Stock-Based Compensation - Schedule of Assumption Used for Fair value of Option (Details) Details 43 false false R44.htm 00000044 - Disclosure - Stock-Based Compensation - Schedule of Unrecognized Stock-Based Compensation (Details) Sheet http://sintx.com/role/Stock-basedCompensation-ScheduleOfUnrecognizedStock-basedCompensationDetails Stock-Based Compensation - Schedule of Unrecognized Stock-Based Compensation (Details) Details 44 false false R45.htm 00000045 - Disclosure - Note Receivable (Details Narrative) Sheet http://sintx.com/role/NoteReceivableDetailsNarrative Note Receivable (Details Narrative) Details http://sintx.com/role/NoteReceivable 45 false false R46.htm 00000046 - Disclosure - Discontinued Operations (Details Narrative) Sheet http://sintx.com/role/DiscontinuedOperationsDetailsNarrative Discontinued Operations (Details Narrative) Details http://sintx.com/role/DiscontinuedOperations 46 false false R47.htm 00000047 - Disclosure - Leases (Details Narrative) Sheet http://sintx.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://sintx.com/role/LeasesTables 47 false false R48.htm 00000048 - Disclosure - Leases - Schedule of Operating Lease Future Minimum Payments (Details) Sheet http://sintx.com/role/Leases-ScheduleOfOperatingLeaseFutureMinimumPaymentsDetails Leases - Schedule of Operating Lease Future Minimum Payments (Details) Details 48 false false All Reports Book All Reports sint-20200930.xml sint-20200930.xsd sint-20200930_cal.xml sint-20200930_def.xml sint-20200930_lab.xml sint-20200930_pre.xml http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true ZIP 64 0001493152-20-021529-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-20-021529-xbrl.zip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~~82^ >I:&YW%"7:&#D*,"%D6M[H$R7L3W\=W4/5Y=%00NIP)+ MOD^']8I9NHDZ; )M@CW"L6$B/(U? HH 'E&D6 L:Q,/_3;P,I9D\DF: ?I?6 M*^@L$!P1C-,//L^4C^[&;LFTQKH]~~

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end